



OPEN ACCESS

EDITED BY

Moriya Tsuji,
Columbia University, United States

REVIEWED BY

Paulo J. G. Bettencourt,
Universidade Católica Portuguesa, Portugal
Keon-Il Im,
LucasBio, Republic of Korea

*CORRESPONDENCE

Karin Schilbach
✉ karin.schilbach@med.uni-tuebingen.de

RECEIVED 30 July 2025

ACCEPTED 07 October 2025

PUBLISHED 11 November 2025

CITATION

Krickeberg N, Rammensee H-G and
Schilbach K (2025) Promiscuous class II-
binding SARS-CoV-2-nuc derived vaccine-
peptide induced extensive conventional,
innate and unconventional T cell responses.
Front. Immunol. 16:1676455.
doi: 10.3389/fimmu.2025.1676455

COPYRIGHT

© 2025 Krickeberg, Rammensee and Schilbach.
This is an open-access article distributed under
the terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses

Naomi Krickeberg¹, Hans-Georg Rammensee^{2,3}
and Karin Schilbach^{1*}

¹Department of Pediatric Hematology and Oncology, University Children's Hospital Tübingen, Tübingen, Germany, ²Institute of Immunology, University of Tübingen, Tübingen, Germany, ³German Cancer Consortium (DKTK), partner site Tübingen, a partnership between DKFZ and University Hospital Tübingen, Germany, Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany

We describe the T-cell response of two healthy SARS-CoV-2-unexposed volunteers to a SARS-CoV-2 nucleoprotein-derived vaccine peptide predicted to promiscuously bind multiple HLA-DR allotypes. NGS-based bulk TCR-repertoire analysis of peptide-specific T-cell responses 4 (D2) and 27 (D1) weeks after vaccination identified CDR3 regions of TCR α , - β , - γ and - δ chains in T cells responding *ex-vivo* to the vaccine peptide LLLDRLLNQLESKMS with IFN γ ⁺-secretion. Adaptive repertoires were unique. Donors shared 15 TCR α and 9 TCR β clonotypes, all public, showing no conserved motifs but TdT-independent "neonatal" CDR3 regions close to the germline. Half the wtSARS-CoV-2 nucleocapsid-reactive adaptive clonotypes show preferential V-segment usage (6/64 V α and 4-8/45 V β chains), and all share/show a N-nucleotide-encoded hydrophobicity in their CDR3 region. V δ C α rearrangements (20.4% and 15.3% of the TCR α -repertoires, respectively), V δ 1C δ $\gamma\delta$ -clonotypes homologous to public CD1-restricted V δ 1⁺ $\gamma\delta$ TCRs, and the induction of "adaptive" V δ 2V γ 9^{negative} T cells support the role of innate T cells in the immune response.

KEYWORDS

SARS-CoV-2, peptide vaccine, SARS-CoV-2 nucleoprotein peptide, T cell response, unconventional T cells, adaptive V δ 2 γ 9^{negative} $\gamma\delta$ T-cells, CD1 restricted, vaccine peptide reactive V δ 1 $\gamma\delta$ T-cells

Introduction

SARS-CoV-2, the causative agent of coronavirus disease 19 (COVID-19), has caused devastating global morbidity and mortality (1) particularly in the elderly (2), people with chronic diseases (3), and co-morbidities such as cancer (4).

Importance of T cell immunity

Globally licensed COVID-19 vaccines focus on humoral immune responses as protective immune mediators (5). However, short duration and limited neutralizing effect against certain virus variants provide only temporary protection and require repeated vaccine boosters. T-cell induction is essential for survival, but specific information on the role and potency of T-cell responses in Covid-19 exposed individuals is still limited. The paramount importance of T cells is demonstrated by the fact that in primary infection B cells rely on a robust response from follicular CD4⁺ T helper cells to develop neutralizing antibodies (6). In contrast, T cells can efficiently control SARS-CoV-2 infection even in the absence of a humoral response (7–13).

Role of memory CD4⁺ T cells

CD4⁺ T cells orchestrate the antiviral adaptive immune response by enhancing CD8⁺ T cell and B cell responses. Memory T cells are the first line of defense against reinfection and generate an immunological memory that can provide lifelong protection against pathogens. Recent studies have shown that SARS-CoV-1 T-cell immunity persists for decades (14) and that virus-specific memory T cells can persist for up to 75 years in humans (15). In addition, it is increasingly recognized that CD4⁺ T cells play an essential role in the control of chronic viral infections (16–18). The development of vaccines that induce effective, and in particular CD4⁺ T-cell responses, is therefore highly attractive.

Objective of the present study

Rammensee et al. designed SARS-CoV-2 HLA-DR T-cell epitopes specifically for their promiscuous binding to multiple HLA-DR alleles covering 97% of the Western population (19). That these peptides were derived from different viral proteins is particularly important because unbiased screens show that T cells from COVID-19 patients recognize SARS-CoV-2 epitopes largely outside the spike protein (20, 21).

Here, we evaluate SARSCoV-2-nuc derived LLLDRLNQLESKMS peptide – designed for promiscuous binding of HLA class II – for its potential to induce a (CD4⁺) T-cell response (19). LLLDRLNQLESKMS was applied – emulsified in Montanide – with Toll-like receptor (TLR) 1/2 agonist XS15 to provide potent activation and maturation of antigen-presenting cells and to prevent vaccine peptides from immediate degradation, thereby supporting the

induction of a potent T-cell response (16). Immune responses were assessed in 2 elderly healthy SARS-CoV-2-unexposed (non-infected, non-recovered) volunteers, both vaccinated in the course of a self-experiment. LLLDRLNQLESKMS-specific T-cell clones were identified *ex vivo* by peptide-induced cytokine secretion and subjected to TCR-bulk sequencing.

In addition to conventional $\alpha\beta$ -T cells, CD1-reactive V δ 1⁺ and adaptive V δ 2⁺ $\gamma\delta$ -T cells, as well as V α /C δ - and V δ /C α clonotypes, were induced. Characteristic features of the immune cell phenotypes responding to the vaccine-peptide, specifically designed for promiscuous binding to HLA class II are shown and discussed.

Materials and methods

Vaccinated individuals

Vaccinated individuals were two healthy, noninfected, non-convalescent volunteers age ≥ 65 . Their HLA class II haplotypes were HLA-DRB1*11:01 (Donor1), and HLA-DRB1*01:01 and HLA-DRB1*11:0401 (Donor2) respectively. For T cell responses Donor 1 was analyzed 4 weeks and Donor 2 five months post inoculation with SARS-CoV-2 nuc Peptide. Vaccination was performed with the synthetic peptide solubilized in water and 20% DMSO including 50 μ g XS15 as an adjuvant, emulsified in Montanide ISA51 VG in a total volume of 0.5 mL. The vaccine was administered as a single subcutaneous injection in the left side of the abdomen.

Why targeting the nucleoprotein: The SARS-CoV-2 spike protein exhibits a markedly higher mutation rate than other viral proteins, estimated at approximately 8×10^{-4} substitutions per site per year, which is around 3–5 times higher than the overall genome average (22, 23). This accelerated evolution drives the emergence of variants with over 30 significant mutations in spike alone, contributing to immune evasion and challenges to vaccine effectiveness (24). In contrast, the nucleoprotein (N) of SARS-CoV-2 is highly conserved with around 90% amino acid sequence identity to SARS-CoV-1 (25) compared to approximately 76% for spike (26), making N a stable target for T cell immunity. Moreover: N is produced at high levels in infected cells, making it an important marker for infection (27). Together, these data justify the choice of nucleoprotein-derived peptides in vaccine design to complement spike-targeted approaches by providing broader and more durable T cell immunity against SARS-CoV-2.

As for the adjuvant XS15: a synthetic, water-soluble derivative of the TLR1/2 ligand Pam3Cys, developed as a peptide vaccine adjuvant by Rammensee et al. (28) activates TLR1/2 heterodimers, stimulating dendritic cells to produce proinflammatory cytokines (IL-8, MCP-1, MIP-1 β) and upregulate activation markers (HLA-DR, CD83, CD86). When admixed with peptides (without covalent coupling), XS15 induces strong CD4⁺ Th1 polarization and CD8⁺ T-cell responses. Its solubility and GMP suitability render it ideal for personalized peptide vaccines. Clinical trials in AML (29), CLL (30), and COVID-19 in B cell deficient patients (31) demonstrated safety and durable immunogenicity, making XS15 a promising adjuvant for personalized tumor and infectious disease vaccines.

Vaccine-peptide LLLDRLNQLESKMS

Reasoning for selecting presentation by MHC class II

Promiscuous MHC class II peptides induce broad CD4⁺ T cell responses by binding multiple HLA-DR, -DP, and -DQ alleles, greatly increase the likelihood of eliciting helper T cell responses in most individuals, regardless of their HLA genotype (32). CD4⁺ T cells support CD8⁺ cytotoxic expansion, license APCs, differentiate into T follicular helper cells for humoral immunity, and exhibit potent recall responses coordinating cellular and humoral arms (33). Moreover, helper epitopes are essential for neoantigens to elicit effective CD8⁺ responses and reveal antitumor immunity against subdominant MHC I-restricted neoepitopes (34). Moreover distinct from CD8⁺ T cells, CD4⁺ T cells display potent recall responses and provide ongoing immunologic surveillance—often being more robust and durable than CD8⁺ responses in both natural infection and vaccination due to their ability to respond to antigen re-encounter and coordinate both cellular and humoral arms of immunity (35).

SARS-CoV-2 nuc-derived peptide LLLDRLNQLESKMS predicted to bind to multiple HLA-DR molecules (HLA-DRB1*01: 01, HLA-DRB1*03:01, HLA-DRB1*04:01, HLA-DRB1*07:01, HLA-DRB1*11:01, HLA-DRB1*15:01) (19) was kindly provided by H.-G. Rammensee. A pipeline for the prediction for promiscuous binding to HLA-DR was established and described by Rammensee et al. (36, 37).

Likelihood of presentation by MHC class I

We also investigated whether shorter variants of this specific peptide are able to bind to a particular HLA class I molecule. For determining HLA restriction computational prediction tools such as NetMHCpan-4.0 were employed (38). The embedded peptide LLLDRLNQL is predicted to be restricted to HLA-A*02 as a weak binder (0.6% rank) (37), with both donors being negative to this allele.

LLLDRLNQLESKMS was part of the multi-peptide vaccine CoVac-1, designed to induce broad T cell immunity against SARS-CoV-2 by including promiscuous HLA-DR-restricted peptides derived from multiple viral proteins, described in the recent study by Rammensee et al., published in Nature (39).

As for the likelihood of SARS-CoV-2 nuc descending peptide LLLDRLNQLESKMS for CD1 presentation we used the Castano CD1d binding algorithm (1-4-7 rule) (Table 1), which shows that hydrophobic peptides can be presented by CD1 when hydrophobic aa are present at positions 1-4-7 (40). Mechanistically, amphipathic or hydrophobic peptides can enter a cell through membrane disruption (41–43) and find their way to lipid droplets (44) where they are subjected to CD1 loading (45).

Immune monitoring

Enrichment of peptide-specific T-cells

Immune monitoring was performed at one timepoint 4 weeks after vaccine administration in Donor 1 and 5 months after the last vaccine administration in Donor 2. PBMCs were isolated from heparinized blood by Ficoll density gradient centrifugation (Biocoll Separating Solution, Bio & SELL) and plated in RPMI supplemented with 5% autologous serum at a density of 1×10^7 cells/ml in a 24-well plate. A total of 6×10^7 PBMCs were plated for each donor respectively. Cells were stimulated with the peptide (LLLDRLNQLESKMS) that was identical in both patient-individualized vaccines. A peptide stimulus was provided on d1 (5 µg/ml), D8 (2,5 µg/ml) and on D15 (2,5 µg/ml). On day 2 cells were split to a density of 5×10^6 cells/ml to avoid bystander activation of T-cells, cells were split again on day 11 to a density of $2,5 \times 10^6$ cells/ml. Fresh medium supplemented with 5% autologous serum was provided twice a week. On day 15, cells that after 5h secreted IFN-γ in response to the peptide stimulus were isolated with the IFN-γ Secretion Assay Cell Enrichment and Detection Kit (Miltenyi Biotec) according to the manufacturer's instructions.

Flow cytometry

Cells were stained before and after IFN-γ enrichment using the following antibodies CD14-FITC (M5E2, BD Pharmingen), CD3-PerCP (SK7, BioLegend), CD4-VioBlue (VIT4, Miltenyi Biotec), CD8-APC-H7 (SK1, BD Pharmingen). Dead cells were excluded using Zombie Aqua™ Fixable Viability Kit (BioLegend). All cells were acquired on a flow cytometer (BD FACSCanto II, BD Biosciences) and flow cytometry results were analyzed using FlowJo™ v10.8 Software (BD Life Sciences).

Molecular methods

RNA extraction

RNA from IFN-γ enriched cells was extracted using the Quick-RNA Microprep or Miniprep Kit (ZymoResearch) according to manufacturer's instructions. Quality and integrity of extracted RNA was evaluated on a Fragment Analyzer System 5300 (Agilent) and concentration of RNA was measured on a Qubit 3 Fluorometer (Thermo Fisher Scientific).

TCR sequencing

Library preparation

α/β T cell receptor libraries were prepared using SMARTer Human TCR a/b Profiling Kit v2 (Takara Bio) according to

manufacturer's instructions with a maximum RNA Input of 273,6 ng for D1 and 151,05 ng for Donor 2. To facilitate sequencing of γ/δ TCRs, γ/δ T cell receptor libraries were prepared with the same kit but with a modified protocol including custom γ/δ primers by the commercial service provider MedGenome Inc. Standardized RNA input for γ/δ TCR libraries was 10 ng for each sample respectively.

NGS sequencing parameters

Sequencing was performed with a MiSeq system (Illumina) using the MiSeq Reagent Kit v3 600-cycle.

Sequencing data analysis

Primary data analysis

The TCR sequencing data was analyzed using the nf-core/airflow pipeline version 2.1.0 (46), which is an open-source pipeline written in Nextflow (47) and available at <http://github.com/nf-core/airflow> as part of the nf-core project (48). The pipeline employs the Immcantation toolset (49–51) for processing of repertoire sequencing data. The sequencing quality of the Illumina MiSeq high-throughput sequencing reads was evaluated with FastQC (52). The pRESTO toolset (49) was used for processing the sequencing reads. Reads were filtered according to base quality (quality score threshold of 20), the forward and reverse reads were paired and a consensus sequence from reads with the same UMI barcodes was obtained, allowing a maximum mismatch error rate of 0.1 per read group. V(D)J sequences were only considered that had at least 2 representative sequences to build the consensus. Sequence copies were calculated as the number of identical sequences with different UMI barcodes. Variable-diversity-joining [V(D)J] germline segments were assigned by aligning the processed sequences to the IMGT database with Change-O and IgBLAST (50, 53). Functional V(D)J sequences were considered part of the same clonal group when they shared the same V(D)J assignment and an identical CDR3. Repertoire characterization was performed with Alakazam and SHazaM (52).

Tools used

Logoplots showing amino acid sequence similarity were generated using Glam2 (54).

Post-processing data analysis of TCRseq data was performed using in-house developed R scripts using R statistical software (v4.1.0) (55) and Rstudio (2023.03.0). R packages used included ggplot2 (v3.3.5) (56), packcircles (v0.3.5) (57) for treeplots and circize (v0.4.13) (58) for chord diagrams for rearrangements.

Clustering of TRB: Clustering of TRB clonotypes was performed using the GLIPH2 (grouping of lymphocyte interactions with paratope hotspots 2) algorithm (59).

Screening for clonotype publicity: Screening for the public nature of a clonotype was performed using the iReceptor Scientific Gateway of the iReceptor platform (60).

Data availability

The subjects' repertoire data are publicly available as part of the AIRR Data Commons on VDJ Server (<https://vdj-dev.tacc.utexas.edu/>) under the permanent identifier c8aa9206-c53f-408b-a517-a74e131547b6. The raw fastq sequencing files have been deposited in NCBI's Sequence Read Archive (SRA) and are accessible under the BioProject PRJNA1232000 through the SRA accession numbers SRR32574224 and SRR32574225.

Study design

PBMCs were isolated from freshly drawn heparinized peripheral blood of the two vaccinated individuals. To amplify vaccine-peptide reactive clones, freshly isolated PBMCs were placed in short-term culture ex vivo with selecting conditions so that only peptide specific T cells would survive due to autologous IL-2 production. For culture details see Sonntag et al (61) and MM section below. T cells responding to the vaccine-peptide pulse with IFN γ secretion were harvested on day 15 (IFN- γ Secretion Assay Cell Enrichment and Detection Kit, Miltenyi Biotec), analyzed by flow cytometry for coreceptor/cytokine expression; vaccine reactive T cell's RNA was extracted and subjected to NGS bulk T cell receptor sequencing (Figure 1).

CDR3 usage for identification/ characterization of the immune response

The CDR3-IMGT is delimited in 5' by the V-REGION 2nd-CYS 104 and in 3' by the J-REGION position 117. IMGT/Junction Analysis explores the JUNCTION that is delimited in 5' by the V-REGION 2nd-CYS 104 and in 3' by the J-REGION J-TRP 118 (for the IGHJ).

Ethic vote

This study was in accordance with the ethical standards of the institutional ethic committee of the Medical Faculty of the Eberhard-Karl-University Tübingen; approved reference: 757/2021B01.

TABLE 1 Vaccine peptide LLLDRLNQLQESKMS.

Peptide	AA position in SARS-Cov-2 nuc	Peptide length
LLL DRL NQLQESKMS Pept.Pos: 1–4–7 (40)	221–235	16

G P A V I L M Aliphatic amino acids, increasing in hydrophobicity from left to right. Amino acid positions that allow CD1 presentation of lipophilic peptides according to Castano et al. (40) are marked in bold and red.




FIGURE 1
Study design. Created in BioRender. (2024). <https://BioRender.com/w63u910>.

Results

Promiscuously MHC class II-binding SARS-CoV2-vaccine-peptide induced a strong CD4⁺ T-cell response in both recipients

Peptide-responsive T cells isolated from enrichment culture via IFN γ -secretion were mostly CD4⁺ in D2 (96%) whereas in D1, vaccinated only 4 weeks prior, also included CD8⁺ T cells (CD8:

46%, CD4: 35%) (Figure 2a). Peptide-responsive T cell's RNA was extracted and subjected to NGS-based TCR-bulk sequencing (Figure 1).

TCR-profiling (Figure 2b) identified 32.411 sequences belonging to 5591 clonotypes with 2183 TCR α and 3376 TCR β clonotypes for D1 and 26. 413 sequences belonging to 1370 clonotypes with 628 TCR α and 736 TCR β clonotypes for D2 (Figure 2b, left). Separate TCR γ / δ repertoire analysis (input: 10ng same cDNA) identified 1693 sequences/244 clonotypes (146 TCR δ and 75 TCR γ clonotypes) for D1 and 228 sequences/68 clonotypes




FIGURE 2 Coreceptor expression of Vaccine peptide reactive T cell pool and rearrangement type of α , β , γ , and δ clonotypes. **(a)** T cells responding to 16mer vaccine peptide with IFN γ secretion included CD8⁺ and CD4⁺ T cells in D1 (analyzed 4 weeks post inoculation) and were almost exclusively CD4⁺ in D2 (five months after inoculation). **(b)** left: TCR α and TCR β clonotypes for donor 1 and donor 2 and TCR γ and TCR δ clonotypes (right). Details of the sequences are given, such as germline configuration, transrearrangements, iNKT clonotype. **(c)** comprehensive visualization of retrieved clonotypes from two separate sequencing runs for α , β , γ , and δ TCR clonotypes, color-coded and grouped by their compositional characteristics. The listed categories are defined as follows: germline category is defined as clones without N-Nucleotide insertions at the V(D)J junctions, germline & TRAV/TRDV_Calpha contains clones that are germline encoded and their α -segment is annotated as both TRAV and TRDV. Transrearranged TRDV-Calpha category comprises all clones in which the TCR α chain is generated by a rearrangement of TRDV1, TRDV2 or TRDV2 to a C α segment. TRAV/TRDV-C α includes all clones in which the TCR α -segment V-Region originated from a segment annotated as both TRAV and TRDV and that are linked to a C α constant region. iNKT clones are characterized by a TCR α chain generated through TRAV24-TRAJ18 rearrangement, "other" categories constitute all remaining clones that don't fall in any of the above-mentioned categories. The following definitions specify the distinct $\gamma\delta$ T-cell clone categories: the transrearranged TRAV-C δ category includes clones characterized by the recombination of TRA V-segment with a C δ constant region. TRAV/TRDV_C δ encompasses clones with a TRDV segment that is classified simultaneously as TRAV and TRDV and are joined to a C δ constant region. V δ 1, V δ 2, V δ 3 categories comprise all clones that exhibit the respective TRDV rearrangement (V δ 1, V δ 2 and V δ 3, respectively).

(35 TCR δ /21 TCR γ clones) in D2 (Figure 2b, right), showing that also innate T-cell compartment responded to the vaccine. The compositional characteristics of the retrieved clonotypes for α , β , γ , and δ TCR chains are displayed in Figure 2c.

CDR3-length profiles reveal focusing of the repertoire

CDR3-length profiles differed from normal Gaussian in both donors in all TCR-chains (Figure 3a). γ -clonotypes were focusing to a specific CDR3 length, δ -clonotypes showed some deviation, similar to CDR3- α/β clonotypes.

Visualization of clonal distribution highlights substantial clonal expansions

Circular tree plots show clonal distributions (Figure 3b). The TOP10 TCR α -clones represented 27.2 and 26.7% of α -sequences in

D1 and D2 (Figure 3c), the TOP10 TCR β -clones represented 29 and 25.8% of the β -sequences in D1 and D2, respectively (Figure 3c). 50% of the TRA-sequences consisted of 55 (D1) and 33 (D2) clonotypes, 50% of the TRB-sequences consisted of 55 (D1) and 38 clones (D2) respectively (Figure 3d).

Preferred V-segment usage in TRAV and TRBV-clonotypes yet highly diverse CDR3 regions

Chord diagrams identified a shared preference for TRAV-segments 13-1, 17, 26-2, and 38-2/DV8 in both donors and a preference for TRBV 5-1, 15, 18 segments in D1 and TRBV-18, 10-3, 9 in D2 (Figure 3e).

A recent landmark study demonstrates that biochemical features are linked to the selection of V-genes (62) with germline-encoded CDR1 region contacting the influenza A virus peptide thereby influencing (for spatial reasons) V-segment usage in TCR α and - β chains. For the same TCRs, it is shown that the germline-




FIGURE 3

Physiochemical features of overlap repertoire. **(a)** The CDR3 length profiles of the α , β , γ , and δ clonotypes of both donors show a similarity of δ to the α and β clonotypes, as they all have a significant number of clonotypes expressing different CDR3 length transcripts, clearly breaking the Gaussian pattern. **(b)** Clonal distribution in α , β , γ , and δ TCR chain clonotypes displayed as circular tree blots. **(c)** The top ten α and top ten β clones in donors 1 and 2, respectively, as a percentage of the total α and β repertoire. **(d)** Number of clonotypes representing 50% of the TRA and TRB immune responses in donors 1 and 2, respectively. **(e)** Chord diagrams showing V(D)J usage reveal the same preferential V segment usage in both donors (highlighted in color).

encoded parts of the CDR3 region of the TCR α chain do not contact the target peptide, but only one or a few N-nucleotide-encoded amino acids which, very importantly, are identical or charge-conserved in TCRs of the same specificity.

Successive studies showed the same result (46, 47). Our results support this as a generally valid *modus operandi* too, assuming that six TRBV-segments used by approximately half of responding $\alpha\beta$ T cells in both donors, with three segments being identical, is a reasonably strong argument. Consistent with hydrophobic target recognition, the CDR1 regions of the preferentially used TRAV-segments (TRAV13-1*01, TRAV17*01, TRAV26-2*01 in both, plus TRAV38-2/DV8 in D1), show up to five aliphatic/hydrophobic amino acids (aa), and CDR1 of TRDV1 four respectively (Table 2).

The CDR2 regions of preferred TRAV segments share the motif SN, consistent with germline-encoded CDR2-binding to conserved regions of the MHC-anchor molecule. The CDR2-loop of the V δ 1-segments is described to interact with lipid-presenting CD1 molecules (63) (Table 2).

In contrast, the corresponding CDR3 regions of these most expanded clonotypes are highly diverse, lack a conserved motif (Table 3), have few N-nucleotides (Table 3, underlined) predominantly encoding aliphatic/hydrophobic aa-insertions.

Public and superpublic TCRs emerge from repertoire alignment

Alignment of repertoires according to identical sequences provides information on the proportion of so-called public TCRs.

The small overlap of repertoire between the donors included 15 TRAV and 9 TRBV-clonotypes, two clonotypes combining a V α with a C δ -segment (TRAV12/TRAJ20 and TRAV12/TRAJ44 with C δ (LPVSF), clonotype TRAV23/DV6/DD2-DJ α - C α (VLPALLSQTQLGSFPPLRP) and the most frequent $\gamma\delta$ -T-cell clone HCSHFDPYSALCV (Table 4). Clonotypes were either derived from rearrangements involving same or different V(D)J segments (convergent CDR3 formation). Logoplots of the overlap repertoire between both donors for TRAV and TRBV-clonotypes reveal a glycine (G) at position 111 in the TRAV clonotypes, whereas the TRBV sequences lack a conserved motif/position (Figure 4a).

TABLE 2 CDR1 and CDR2 Regions of the most frequently used TRAV segments and the V δ 1 segment.

Germline_v_call	CDR1	CDR2
TRAV13-1*01	DSASAY	IRSNVGE
TRAV17*01	TSINN	IRSNERET
TRAV26-2*01	TISGTDY	GLTSSN
TRAV38-2/DV8	PVRVII	KKLISNR
TRDV1	TSWWSYY	QGS

Motif SN (blue, italic) is present in the CDR2 regions in the most common TRAV segments and additionally in CDR1 of TRAV 13. V δ 1 segment contains 4 highly aliphatic aa in its CDR1 and S (blue and bold) in its CDR2 segment. Aliphatic amino acids are given in red and bold.

Overlap and adaptive clonotypes resemble neonatal TCRs

Recent studies have shown that the adaptive TCR repertoire consists of two ontogenetically and functionally distinct TCR types, which are regulated by variations in thymic production and terminal deoxynucleotidyl transferase (TDT) activity (27). Strikingly, the CDR3 sequences of the overlap repertoire and the most common vaccine-reactive $\alpha\beta$ T clonotypes (Table 5) lack or have only few N nucleotides, assigning them to the neonatal TCRs derived from TDT-negative precursors, which persist throughout life, are highly shared between individuals and are reported to be disease-associated (27).

In line with these findings, we also found germline-encoded TCRs making up 8.11% (177/2183) and 7.8% (49/2682) of TRAV-clonotypes in D1/D2, and 2.13 and 0.68% of TRBV-clonotypes in D1/D2 respectively.

In contrast to the TDT-negative precursors, TDT-dependent TCRs with distinct structural features and less shared among subjects (64) was unexpectedly represented by a $\gamma\delta$ T-cell clone (HCSHFDPYSALCV Table 3, TRD bottom line) and a V α J δ C α hybrid clone (VLPALLSQTQLGSFPPLRP, Table 4) in the overlap repertoire.

Both sequences showing atypical features with 58 and 48 Np1 inserts between V- and D-region and 22 and 8 Np2 inserts between D- and J-region respectively (Table 4).

Search for motifs in $\alpha\beta$ -clonotypes

TOP10 SARS-CoV2nuc-reactive clonotypes are completely diverse and superpublic

To analyze the entirety of $\alpha\beta$ -clonotypes in a biologically meaningful way (65–67) TOP10 clonotypes, which can be considered immunodominant due to their prevalence, and the most common V(D)J-rearrangements were examined for conserved positions/sequence similarities in their CDR3 region. TOP10 clonotypes (Table 5) were not similar to each other nor were they identified in the TCR-repertoire of the other donor. They also did not show a conserved motif (Figure 4b), but in both donors the majority of TOP10 clonotypes was superpublic (present in a large proportion of a studied population) and annotated in public databases as part of Covid-19 immune responses (Table 5).

Also, most frequent V(D)J-rearrangements had no conserved motif in their CDR3 regions (Table 3).

Clonotypes with most frequent CDR3-length are exclusively private

Clonal expansions can significantly bias CDR3-length distribution. Yet, GLIPH2 algorithm analysis of most frequent CDR3 length clonotypes (D1: 45 nucleotides; 742 clonotypes, D2–42 nucleotides: 135 clonotypes) identified very few and small clusters. A tiny TRB-cluster with similar motif (Figure 4c) was

TABLE 3 Identical V segments usage in D1 and D2 by the most expanded TRAV and TRBV clonotypes (n≥1000).

Most highly expanded clonotypes carrying the most commonly used TRAV segments (left) and TRB segment (right)								
TRA				TRB				
Donor	CDR3	V	J	Donor	CDR3	V	D	J
D1	CATD <u>A</u> RTGRRALTF	TRAV17	TRAJ5	D1	CASS <u>I</u> RQGVNTEAFF	TRBV18	TRBD1	TRBJ1-1
	CAAV <u>N</u> AGGTSYGKLTf	TRAV13-1	TRAJ52		CASSP <u>S</u> PGTDTQYF	TRBV18		TRBJ2-3
	CATD <u>R</u> KGSSASKIIF	TRAV17	TRAJ3		CASSP <u>S</u> KQGLSPLHF	TRBV18	TRBD1	TRBJ1-6
	CAAS <u>P</u> RII <u>Q</u> GAQKLf	TRAV13-1	TRAJ54		CASSP <u>T</u> GGAMNEQFF	TRBV18	TRBD1	TRBJ2-1
	CAAR <u>G</u> VYNFNKFYF	TRAV13-1	TRAJ21		CASSP <u>K</u> VGT <u>K</u> GSNEQFF	TRBV18	TRBD2	TRBJ2-1
	CAAR <u>A</u> DKLIF	TRAV13-1	TRAJ34		CASSP <u>R</u> L <u>T</u> G <u>S</u> GNLPHF	TRBV18	TRBD1	TRBJ1-6
	CAT <u>A</u> TNSGGYQKVTF	TRAV17	TRAJ13		CASSP <u>G</u> TGA <u>Y</u> NEQFF	TRBV18	TRBD1	TRBJ2-1
	CAAS <u>I</u> GIYNFNKFYF	TRAV13-1	TRAJ21		CASSP <u>R</u> SSGGANTGELFF	TRBV18	TRBD1	TRBJ2-2
	CAT <u>G</u> LL <u>I</u> QGAQKLf	TRAV17	TRAJ54		CASSP <u>R</u> LAGGLSSYNVQFF	TRBV18	TRBD2	TRBJ2-1
	CAS <u>R</u> GASKIIF	TRAV13-1	TRAJ3		CASSP <u>R</u> AGT <u>G</u> SPGELFF	TRBV18	TRBD1	TRBJ2-2
	CAALSYNQGGKLIF	TRAV13-1	TRAJ23		CASSP <u>G</u> STTGELFF	TRBV18		TRBJ2-2
	CATSGGNNRLAF	TRAV17	TRAJ7		CASSP <u>A</u> SGRAGANVLTF	TRBV18	TRBD2	TRBJ2-6
	CAQSTYNQGGKLIF	TRAV13-1	TRAJ23		CASSP <u>A</u> PGQTNEQYF	TRBV18	TRBD1	TRBJ2-7
	CAP <u>R</u> NGSGGTSYGKLTf	TRAV13-1	TRAJ52		CASSP <u>G</u> ARNSPLHF	TRBV18	TRBD1	TRBJ1-6
	CA <u>E</u> TGNQFYF	TRAV17	TRAJ49		CASS <u>I</u> K <u>T</u> CNPLVNNEQFF	TRBV18	TRBD1	TRBJ2-1
D2	CAAS <u>I</u> LGGNQFYF	TRAV13-1	TRAJ49	D2	CASSRSPGQADTQYF	TRBV18		TRBJ2-3
	CIL <u>V</u> TSGYKYIF	TRAV26-2	TRAJ40		CASSP <u>G</u> TGNTEAFF	TRBV18	TRBD1	TRBJ1-1
	CIL <u>R</u> GGNTGNQFYF	TRAV26-2	TRAJ49		CASSISSGSTDSTQYF	TRBV18	TRBD2	TRBJ2-3
	CIL <u>R</u> VWGFNEKLTF	TRAV26-2	TRAJ48		CASS <u>I</u> NYVRQETQYF	TRBV18	TRBD1	TRBJ2-5
	CAASHSGNTPLVF	TRAV13-1	TRAJ29		CASS <u>A</u> STGVNEQFF	TRBV18	TRBD1	TRBJ2-1
	CILLSGNTPLVF	TRAV26-2	TRAJ29		CASSP <u>L</u> GTSGRNQETQYF	TRBV18	TRBD2	TRBJ2-5
	CAASTSGTYKYIF	TRAV13-1	TRAJ40		CASSRGTGAINVLTF	TRBV18	TRBD1	TRBJ2-6
	CAASSNGGNQFYF	TRAV13-1	TRAJ49		CASSP <u>V</u> KVALSGNTIYF	TRBV18		TRBJ1-3
	CIL <u>K</u> GGNAGNMLTF	TRAV26-2	TRAJ39		CASSP <u>V</u> PIGVGTDTQYF	TRBV18		TRBJ2-3
	CIL <u>R</u> DWGEKLTF	TRAV26-2	TRAJ48		CASSP <u>S</u> IVSGHEQYF	TRBV18		TRBJ2-7

(Continued)

TABLE 3 Continued

Most highly expanded clonotypes carrying the most commonly used TRAV segments (left) and TRB segment (right)									
TRA					TRB				
Donor	CDR3	V	J	Donor	CDR3	V	D	J	
	CILRDYVAFNGNEKLTF	TRAV26-2	TRAJ48		CASSPGLVGSSEQFF	TRBV18		TRBJ2-1	
	CAASTSGTYKYIF	TRAV13-1	TRAJ40		CASSKSPFNTGELFF	TRBV18		TRBJ2-2	
	CAASKPGNNRKKLI	TRAV13-1	TRAJ38		CASSPSSKGTGAYEQYF	TRBV18	TRBD1	TRBJ2-7	
	CAARSDNRLAF	TRAV13-1	TRAJ7		CASSRGTNNSPLHF	TRBV18	TRBD2	TRBJ1-6	
	CAASLYGCSQGNLIIF	TRAV13-1	TRAJ42		CASSRQRQFEQYF	TRBV18		TRBJ2-7	

TRAV segments (left) and TRB segment (right). Aliphatic (hydrophobic) amino acids given in red and bold, basic amino acids in green and bold. N nucleotide encoded aa are underlined.

present in both donors, yet the vast majority of clonotype-clusters was completely private in both donors (not shown).

A private clonotype-cluster refers to a group of immune cells (typically T or B lymphocytes) that share highly similar or identical antigen receptor sequences, but are unique to a single individual, sample, or patient, rather than being found across multiple individuals. This distinguishes them from public clonotypes, which are shared between different individuals and often reflect common immunological responses to well-conserved antigens.

Immunodominant clonotypes show N-nucleotide encoded hydrophobicity in their CDR3 region

To identify consensus criteria of vaccine-reactive clonotypes we followed Ritmahan et al (68) who showed that factors that determine whether a response becomes immunodominant (ID) per donor is that their CDR3 regions distinctively show hydrophobic aa residues compared to the subdominant (SD) responses. Since the common V-J combinations are shared between ID and subdominant SD responses, the authors assume that the biased V-J recombination events are restricted by epitope specificity; immunodominance however resulting from detectable distinctive amino acid enrichments i.e. hydrophobic amino acids in D-N encoded CDR3 regions. We found matching results.

Removing the conserved V- and J-regions of the CDR3 sequences at the terminal ends, leaves a “non-VJ”-region as core sequence encoded by randomly inserted nucleotides. For TRAV-sequences between V and J, for TRB-segments encoded by D-segment and N-nucleotide insertions. Immunodominant clonotypes, i.e. TOP10 TRAV/TRBV-clonotypes (Table 5) and clonotypes incorporating preferred V-(D)-J rearrangements (Table 3) coherently show hydrophobic (aliphatic) amino acids (listed for increasing hydrophobicity: G,P,A,V,I,L,M,F,W) in their N-nucleotide encoded CDR3 regions (red).

We find germline-encoded CDR3 clonotypes combine aliphatic with basic amino acids, immunodominant CDR3 clonotypes combining aliphatic with basic or neutral polar uncharged amino acids (Table 3), while rarer clonotypes combine aliphatic amino acids with electrically charged amino acids (not shown). Importantly, 7/11 TdT-independent “neonatal” TCR clonotypes, which have N-nucleotides, if any, have aliphatic/hydrophobic amino acid “insertions” (Table 4).

Vδ1-Cα clonotypes link αβTCR diversity with innate-like recognition

Classically TCR-chains are encoded by genes formed by elements belonging to the same locus. However, trans-rearrangements between V(D)JC elements belonging to different TCR-chain loci have been described (69–73), most of them fusing Vγ and (D)Jβ elements, which are translated into functional

TABLE 4 Overlap repertoire TRA, TRB, TRD Overlap sequences lack or show only few N nucleotides.

Locus	Rearrange- ment	CDR3 V	...N...	J	V-segment	D segment	J segment	Np1_length	Np2_length	Donor	# of clones	CDR3 sequence	Public
TRA	VαCα	CAG	RRR	QGAQKLVF	TRAV35*01		TRAJ54*01	8		D1+D2	1 (D1)/2 (D2)	Ident.	+
	VαCα	CAYRS	F	SGNTPLVF	TRAV38-2/ DV8*01		TRAJ29*01	5 (D1)/3 (D2)		D1+D2	1 (D1)/1 (D2)	Con.	+
	VαCα	CAYRS		YGGSQGNLIF	TRAV38-2/ DV8*01		TRAJ42*01	2 (D1)/0 (D2)		D1+D2	1 (D1)/1 (D2)	Con.	+
	VαCα	CILR	V	NFGNEKLTF	TRAV26-2*01		TRAJ48*01	2 (D1)/3 (D2)		D1+D2	1 (D1)/1 (D2)	Con.	+
	VαCα	CILR	AP	FGNEKLTF	TRAV26-2*01		TRAJ48*01	4 (D1+D2)		D1+D2	1 (D1)/1 (D2)	Ident.	+
	VαCα	CA	V	TGNQFYF	TRAV13-1*01		TRAJ49*01	5 (D1)		D1	1 (D1)	Con.	+
		CAV		TGNQFYF	TRAV21*01		TRAJ49*01	0 (D2)		D2	1 (D2)		+
	VαCα	CAA	R	DTGRRALTF	TRAV13-1*01		TRAJ5*01	3 (D1)		D1	1 (D1)	Con.	+
					TRAV13-1*02		TRAJ5*01	0 (D1+D2)		D1+D2	1 (D1)/1 (D2)	Con.	+
	VαCα	CAAS	KA	GRRALTF	TRAV13-1*01		TRAJ5*01	3 (D1)		D1	1 (D1)	Ident.	+
					TRAV13-1*02		TRAJ5*01	3 (D2)		D2	1 (D2)		+
	VαCα	CAAS		TSGTYKYIF	TRAV13-1*01		TRAJ40*01	0 (D1)		D1	1 (D1)	Con.	+
					TRAV13-1*02		TRAJ40*01	0/2 (D2)		D2	6 (D2)	Con.	+
	VαCα	CAAS		NQGGKLIF	TRAV13-1*01		TRAJ23*01	3 (D1)		D1	1 (D1)	Ident.	+
					TRAV13-1*02		TRAJ23*01	4 (D2)		D2	1 (D2)		+
	VαCα	CA	L	RDDKIIF	TRAV21*01		TRAJ30*01	0 (D1)		D1	1 (D1)	Con.	+
		CAL		RDDKIIF	TRAV19*01		TRAJ30*01	0 (D2)		D2	1 (D2)		+
	VαCα	CAV		NSGGYQKVTF	TRAV2*01		TRAJ13*02	1 (D1)		D1	2 (D1)	Con.	+
		CAVN		SGGYQKVTF	TRAV12-2*01		TRAJ13*02	0 (D2)		D2	1 (D2)	Con.	+
	VαCα	CAA	P	NTGNQFYF	TRAV29/DV5*04		TRAJ49*01	1 (D1)		D1	1 (D1)	Con.	+
					TRAV29/DV5*01		TRAJ49*01	3 (D2)		D2	1 (D2)		+
	VαCα	C	D	NNNDMRF	TRAV16*01		TRAJ43*01	0 (D1+D2)		D1+D2	1 (D1+D2)	Ident.	+
	VαCα	CAA	L	DTGRRALTF	TRAV13-1*01		TRAJ5*01	1 (D1+D2)		D1+D2	1 (D1+D2)	Con.	+
	VαJδCα	VLPAL	L	SQTQLGSFPPLRP	TRAV23/DV6*01	TRDD2*01	TRDJ4*01	48 (D1+D2)	8 (D1+D2)	D1+D2	1 (D1+D2)	Ident.	no
TRB	VβCβ	CASSHGTSGR	L	GELFF	TRBV3-1*01	TRBD2*02	TRBJ2-2*01	1	3 (D1)/2 (D2)	D1+D2	1 (D1)/1 (D2)	Con.	+

(Continued)

TABLE 4 Continued

Locus	Rearrange- ment	CDR3 V	...N...	J	V-segment	D segment	J segment	Np1_length	Np2_length	Donor	# of clones	CDR3 sequence	Public
	VβCβ	CASS P	G IS	SYEQYF	TRBV18*01		TRBJ2-7*01	8 (D1)/9 (D2)		D1+D2	1 (D1)/1 (D2)	Con.	+
	VβCβ	CASS L	S IS	TDTQYF	TRBV11-2*03		TRBJ2-3*01	9 (D1)		D1	1 (D1)	Con.	+
					TRBV11-2*01		TRBJ2-3*01	7/6 (D2)		D2	2 (D2)	Con.	+
	VβCβ	CASS	P SNG	AKNIQYF	TRBV7-2*01		TRBJ2-4*01	11 (D1)/12 (D2)		D1+D2	1 (D1)/1 (D2)	Con.	+
	VβCβ	CASS P GT G	R	TGELFF	TRBV18*01,	TRBD1*01	TRBJ2-2*01	1 (D1)/0/1 (D2)	3(D1)/2/3 (D2)	D1+D2	1 (D1)/2 (D2)	Con.	+
	VβCβ	CASS P	S P	A NTGELFF	TRBV18*01		TRBJ2-2*01	8 (D1+D2)		D1+D2	1 (D1)/1 (D2)	Con.	+
	VβCβ	CASS L GG		G NQPQHF	TRBV12-3*01	TRBD1*01	TRBJ1-5*01	0 (D1)/8 (D2)	1 (D1+D2)	D1+D2	1 (D1)/1 (D2)	Con.	+
	VβCβ	CAS R AG	A	NNEQFF	TRBV7-9*01	TRBD2*01	TRBJ2-1*01	1 (D1)	3 (D2)	D1	1 (D1)	Con.	+
					TRBV7-9*03	TRBD2*01	TRBJ2-1*01	1 (D2)	5 (D2)	D2	6 (D2)	Con.	+
TRD	VβCβ	CASS L	S	A TNEKLF	TRBV12-3*01		TRBJ1-4*01	5 (D1)/4 (D2)		D1+D2	1 (D1)/2 (D2)	Con.	+
	VαCδ	LPV S F			TRAV12-1*01		TRAJ44*01	8 (D1+D2)		D1+D2	1 (D1+D2)	Ident.	+
							TRAJ20*01	8 (D1+D2)		D1+D2	1 (D1+D2)	Ident.	+
	VδCδ	HCSH F LD P YS A LCV			TRAV36/DV7*01	TRDD2*01	TRDJ2*01	58 (D1+D2)	22 (D1+D2)	D1+D2	1 (D1)	Ident.	no

CDR3 regions are displayed in bold. Aliphatic amino acids are given in red, basic amino acids in green. Abbreviations in CDR3 sequence column: "ident." for identical sequences, "con." for convergent sequences. Convergent sequences show the same nucleotide sequence but are derived from rearrangements involving different VDJ segments. Screening for the public nature of a clonotype was performed using the iReceptor Scientific Gateway of the iReceptor platform (35).




FIGURE 4

Consensus sequences. (a) CDR3 α and β chain LOGO BLOTS of the overlap repertoire show the conservation of a glycine (G) at position 111 in the TRA clonotypes, in contrast TRBV sequences lack a conserved motif/position. (b) Top 10 TRAV and TRBV clonotypes (immunodominant) show no sequence/motif conservation but are highly individual. (c) D1 and D2 clonotypes of most frequent TRB CDR3 length are private (not shown), only one tiny cluster is shared between the donors (D1 n=4, D2 n=6 clonotypes). (d) Vδ1Cα clonotypes grouped in 4 (D1), respectively 1 cluster (D2) share motifs with Covid-19 reactive TRAV $\alpha\beta$ T cell clonotypes (YGGSQGN, YSSASKIIF, DDKIIF) 62,63,64.

antigen-receptor chains that couple with TCR α -chains (74). $\gamma\beta$ -clonotypes were absent in our study. However, the δ -locus (8 variable segments) is interspersed within the α -locus, and each of the V δ -genes can productively rearrange to a J α -segment, producing functional V δ -J α -C α chains that can pair with a TCR β chain and form functional $\alpha\beta$ -TCRs (74, 75). Vδ1, the most upstream V δ -gene-segment, can rearrange to almost all J α -gene-segments (76), which we found confirmed in the Vδ1-Cα sequences of D1 and D2 (42(1.4%) and 9(0.9%) of TRAV-clonotypes respectively), carrying J-segments derived from the entire J α -gene locus (J α 3 to J α 48 in D1, J α 9 to J α 49 in D2). No Vδ2-Cα, Vδ3-Cα, or V γ -C β trans-rearrangements were identified (77).

Four Vδ1-Cα clonotype-clusters in D1 share motifs with public Covid-19 reactive TRAV $\alpha\beta$ -T-cell clonotypes (Figure 4d): YGGSQGN is the major motif in Covid 19-reactive TRAV-clonotypes of CD4⁺ $\alpha\beta$ -T cells in reconvalescent individuals (78), YSSASKIIF characterizes the TRAV19-J α 3 rearrangement in a Covid-specific CD8⁺ $\alpha\beta$ -T cell clone (79) and motif DDKIIF is part of a public $\alpha\beta$ -TCR specific for the highly hydrophobic Covid-derived spike peptide YLQPRTFL (80).

Six Vδ1-Cα sequences, detected in D2, formed two clusters (three and two sequences, with almost identical sequences) (Supplementary Table 1).

Vδ1-Cα clonotypes represent a distinct subset integrated within the $\alpha\beta$ TCR repertoire

CDR3 consensus of Vδ1-Cα-clonotypes show an N-nucleotide encoded 3-aa motif between germline-derived 5' and 3' ends with charge conservation for hydrophobicity (blue horizontal line) (Figure 5a). The CDR3 consensus generated from the α -clonotypes of the overlap repertoire (third line) shows the basic but lacks the aliphatic (AA)-residues.

Vδ1Cα- $\alpha\beta$ TCRs via their Vδ1-segment are preprogrammed in their CDR1/2 binding specificity for CD1 and MHC. They may act as pattern recognition receptors (PRR) for MHC molecules that are upregulated under inflammatory conditions, thus may represent a unique aspect of epithelial barrier immunity, combining innate biology with adaptive receptors.

The unexpected identification of VδCα-hybrid clonotypes led us to search for VδCδ and V γ C γ clonotypes in the vaccine-reactive T-cell pools.

Vaccine-reactive $\gamma\delta$ -clonotypes

$\gamma\delta$ -TCRs can recognize polypeptides that are soluble or membrane-anchored and cross-linked to MHC or MHC-like

TABLE 5 TRA and TRB top 10 clonotypes in D1 and D2.

Top 10 Clonotypes										
TRA					TRB					
Donor	CDR3	V	J	Public +/-	Donor	CDR3	V	D	J	Public +/-
D1	CAY <u>RS</u> <u>SR</u> FGNEKLTF	TRAV38-2/ DV8*01	TRAJ48*01	+	D1	CAT <u>S</u> <u>R</u> <u>GV</u> <u>Q</u> <u>Q</u> <u>RL</u> RTGELFF	TRBV15*02	TRBD1*01	TRBJ2-2*01	-
	CATD <u>A</u> <u>R</u> <u>T</u> <u>G</u> <u>RR</u> ALTF	TRAV17*01	TRAJ5*01	+		CASS <u>R</u> <u>SS</u> <u>G</u> <u>L</u> <u>P</u> SYEQYF	TRBV5-1*01	TRBD2*02	TRBJ2-7*01	-
	CATD <u>R</u> <u>K</u> <u>C</u> SSASKIIF	TRAV17*01	TRAJ3*01	-		CASS <u>S</u> <u>Y</u> <u>S</u> <u>G</u> <u>S</u> <u>N</u> <u>Q</u> <u>P</u> <u>Q</u> <u>H</u> <u>F</u>	TRBV6-5*01	TRBD2*01	TRBJ1-5*01	+
	CA <u>A</u> <u>V</u> <u>N</u> <u>A</u> <u>G</u> <u>G</u> <u>T</u> <u>S</u> <u>Y</u> <u>G</u> <u>K</u> <u>L</u> <u>T</u> <u>F</u>	TRAV13-1*02	TRAJ52*01	+		CAS <u>S</u> <u>E</u> <u>S</u> <u>F</u> <u>M</u> <u>A</u> <u>Y</u> <u>E</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV6-1*01		TRBJ2-7*01	-
	CA <u>V</u> <u>S</u> <u>V</u> <u>T</u> <u>G</u> <u>G</u> <u>F</u> <u>K</u> <u>T</u> <u>I</u> <u>F</u>	TRAV8-4*01	TRAJ9*01	+		CASS <u>S</u> <u>A</u> <u>Y</u> <u>E</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV7-2*02		TRBJ2-7*01	+
	CA <u>V</u> <u>R</u> <u>L</u> <u>S</u> <u>N</u> <u>T</u> <u>G</u> <u>N</u> <u>Q</u> <u>F</u> <u>Y</u> <u>F</u>	TRAV41*01	TRAJ49*01	+		<u>C</u> <u>S</u> <u>G</u> <u>V</u> <u>G</u> <u>G</u> <u>Y</u> <u>E</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV29-1*01	TRBD1*01	TRBJ2-7*01	+
	CA <u>A</u> <u>S</u> <u>M</u> <u>R</u> <u>T</u> <u>S</u> <u>Y</u> <u>G</u> <u>K</u> <u>L</u> <u>T</u> <u>F</u>	TRAV23/DV6*01	TRAJ52*01	+		CASS <u>I</u> <u>R</u> <u>Q</u> <u>G</u> <u>V</u> <u>N</u> <u>T</u> <u>E</u> <u>A</u> <u>F</u> <u>F</u>	TRBV18*01	TRBD1*01	TRBJ1-1*01	+
	CA <u>V</u> <u>Q</u> <u>D</u> <u>T</u> <u>Q</u> <u>C</u> <u>T</u> <u>G</u> <u>N</u> <u>Q</u> <u>F</u> <u>Y</u> <u>F</u>	TRAV20*02	TRAJ49*01	-		CASS <u>D</u> <u>S</u> <u>G</u> <u>G</u> <u>G</u> <u>I</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV6-1*01	TRBD2*01	TRBJ2-4*01	+
	CA <u>A</u> <u>S</u> <u>P</u> <u>R</u> <u>I</u> <u>I</u> <u>Q</u> <u>G</u> <u>A</u> <u>Q</u> <u>K</u> <u>L</u> <u>V</u> <u>F</u>	TRAV13-1*02	TRAJ54*01	-		CASS <u>L</u> <u>G</u> <u>T</u> <u>G</u> <u>R</u> TGELFF	TRBV5-5*01	TRBD1*01	TRBJ2-2*01	+
	CGGNNRLAF	TRAV12-2*01	TRAJ7*01	+		CAS <u>R</u> <u>E</u> <u>G</u> <u>A</u> <u>T</u> <u>Y</u> <u>E</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV7-9*01	TRBD1*01	TRBJ2-7*01	+
D2	CATD <u>E</u> <u>S</u> <u>A</u> <u>A</u> <u>L</u> <u>I</u> <u>F</u>	TRAV17*01	TRAJ15*01	-	D2	CASS <u>V</u> <u>R</u> <u>A</u> <u>L</u> <u>A</u> <u>G</u> <u>P</u> <u>D</u> <u>T</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV9*01	TRBD2*02	TRBJ2-3*01	+
	CA <u>A</u> <u>S</u> <u>I</u> <u>L</u> <u>G</u> <u>G</u> <u>N</u> <u>Q</u> <u>F</u> <u>Y</u> <u>F</u>	TRAV13-1*02	TRAJ49*01	+		CAISE <u>G</u> <u>L</u> <u>A</u> <u>G</u> <u>V</u> <u>Y</u> <u>E</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV10-3*02	TRBD2*02	TRBJ2-7*01	+
	CAY <u>R</u> <u>S</u> <u>Q</u> <u>S</u> <u>G</u> <u>N</u> <u>T</u> <u>P</u> <u>L</u> <u>V</u> <u>F</u>	TRAV38-2/ DV8*01	TRAJ29*01	+		CASS <u>R</u> <u>S</u> <u>P</u> <u>G</u> <u>Q</u> <u>A</u> <u>D</u> <u>T</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV18*01		TRBJ2-3*01	+
	<u>C</u> <u>L</u> <u>G</u> <u>M</u> <u>D</u> <u>T</u> <u>G</u> <u>RR</u> ALTF	TRAV22*01	TRAJ5*01	+		CASS <u>P</u> <u>G</u> <u>T</u> <u>G</u> <u>N</u> <u>T</u> <u>E</u> <u>A</u> <u>F</u> <u>F</u>	TRBV18*01	TRBD1*01	TRBJ1-1*01	+
	CAY <u>R</u> <u>G</u> <u>R</u> <u>G</u> <u>G</u> <u>S</u> <u>N</u> <u>Y</u> <u>K</u> <u>L</u> <u>T</u> <u>F</u>	TRAV38-2/ DV8*01	TRAJ53*01	+		<u>C</u> <u>S</u> <u>G</u> <u>W</u> <u>L</u> <u>A</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>E</u> <u>T</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV29-1*01	TRBD2*02	TRBJ2-5*01	-
	CIL <u>V</u> <u>T</u> <u>S</u> <u>G</u> <u>T</u> <u>Y</u> <u>K</u> <u>Y</u> <u>I</u> <u>F</u>	TRAV26-2*01	TRAJ40*01	+		CAS <u>R</u> <u>A</u> <u>G</u> <u>A</u> <u>N</u> <u>N</u> <u>E</u> <u>Q</u> <u>F</u> <u>F</u>	TRBV7-9*03	TRBD2*01	TRBJ2-1*01	+
	CA <u>P</u> <u>R</u> <u>R</u> <u>N</u> <u>D</u> <u>Y</u> <u>K</u> <u>L</u> <u>S</u> <u>F</u>	TRAV17*01	TRAJ20*01	+		CASS <u>I</u> <u>S</u> <u>S</u> <u>G</u> <u>T</u> <u>S</u> <u>T</u> <u>D</u> <u>T</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV18*01	TRBD2*02	TRBJ2-3*01	+
	CATD <u>R</u> <u>G</u> <u>G</u> <u>G</u> <u>N</u> <u>K</u> <u>L</u> <u>T</u> <u>F</u>	TRAV17*01	TRAJ10*01	+		CASS <u>L</u> <u>N</u> <u>Y</u> <u>V</u> <u>R</u> <u>G</u> <u>Q</u> <u>E</u> <u>T</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV18*01	TRBD1*01	TRBJ2-5*01	-
	CAT <u>G</u> <u>H</u> <u>T</u> <u>G</u> <u>RR</u> ALTF	TRAV17*01	TRAJ5*01	+		CASS <u>A</u> <u>G</u> <u>L</u> <u>A</u> <u>G</u> <u>E</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV2*01	TRBD2*01	TRBJ2-7*01	+
	CIL <u>R</u> <u>G</u> <u>G</u> <u>N</u> <u>T</u> <u>G</u> <u>N</u> <u>Q</u> <u>F</u> <u>Y</u> <u>F</u>	TRAV26-2*01	TRAJ49*01	+		CASS <u>P</u> <u>L</u> <u>G</u> <u>T</u> <u>S</u> <u>C</u> <u>R</u> <u>N</u> <u>Q</u> <u>E</u> <u>T</u> <u>Q</u> <u>Y</u> <u>F</u>	TRBV18*01	TRBD2*02	TRBJ2-5*01	-

N-Nucleotide encoded amino acids are underlined and bold, aliphatic amino acids are red and bold, basic amino acids are green and bold. Screening for the public nature of a clonotype was performed using the iReceptor Scientific Gateway of the iReceptor platform (35).




FIGURE 5

Search for motif conservation. In (a) Comparison of CDR3 consensus sequences of Vδ1Cα with TRAV overlap (b) Comparison of Vδ1Cδ CDR3 consensus sequences in D1/D2 (c) Homology of public CD1 reactive γδ TCRs; Left: comparison public CD1 reactive TCRδ clonotypes with vaccine peptide reactive TRDVδ1 chain clonotypes containing (Y)WG(I), Right: TCRγ chain clonotypes manually clustered compared to consensus TCRγ CDR3 sequences of public CD1-restricted TCRγ clonotypes.

molecules (81) including CD1b, CD1c, CD1d and MHC class I-related protein 1 (MR1), recognizing antigen, antigen presenting molecule or both either via germline-encoded regions of the receptor, reminiscent of PRRs, or adaptive antigen binding via the CDRs (82–85). In doing so, γδ-T cells are not restricted to the contact mode of αβ-TCRs but can approach their ligands from many directions (86).

Most Vγ-clonotypes are Vγ9^{negative} and homologous to public CD1-restricted TCRγ-clonotypes

A putative CD1 presentation of the lipophilic vaccine peptide was investigated by aligning the sequences of public CD1-restricted TCR sequences with the γ- and δ-clonotypes of D1 and D2.

The public CD1-restricted TCRs DP10.7 (87), CO3 (88), BC14.1 (89) CDR3 TCRγ-chain region 5'-motif CATWD is germline-encoded, provided by TRGV-segments 1-8, the 3'-motif YYKKLF is derived from TRGJ1. (Figure 5c, Table 6A) (87–89).

About half of the vaccine-reactive γ-clonotypes in both donors were TRGV1-8⁺ thus Vγ9^{negative} and their γ-chain CDR3-region homologous to CD1-reactive γδ-T cells (Figure 5c), and the most common TCRγ clonotype (n=12) in D2 with the exception of 1 amino acid was identical with the public CD1-restricted CO3 TCRγ-clonotype CATWDGDYYKKLF (convergent CDR3 formation). TRGV4-TRGJ1 as well as other TRGV-TRGJ rearrangements used by public CD1-reactive TCRs were present in D1 and D2 (Table 5A).

The significant proportion of Vγ10-clonotypes in our analysis represent most likely “unproductive” γ-alleles of peptide-responsive αβ-T cells (90), in the vaccine-reactive T-cell pool (not shown).

Vaccine-reactive Vδ1⁺ TCR clonotypes bear the CD1-restricted WGI/Y motif

CD1-restricted γδ-TCRs contact CD1 through a Vδ1-segment containing a germline-encoded WGI/Y motif (91). WGI/Y bearing Vδ1-segments of both donors (Figure 5b), when aligned with public CD1-restricted Vδ1-clonotypes show strong homology with these, clearly supporting a presentation of the hydrophobic peptide LLLDRLNQLESKMS by CD1-molecules (Figure 5c, Table 6B).

Vδ1-clonotypes with germline-derived LGD motif assigns them to the adaptate virus-reactive γδ-T-cell compartment

D1's Vδ1-repertoire had an additional germline-derived motif: LGD (Figure 5b). While the WGI/Y motif is associated with CD1 recognition, LGD containing public CDR3 sequence TRDV1-TRDD3-CALGELGD was previously shown to be expanded in CMV-infection and assumed to belong to the “adaptate” γδ-T-cell compartment, representing a radically new adaptive immunobiology (92) which displays potent cytolytic function against virally infected and malignant cells, strong cytokine production and expression of

TABLE 6 SARS-CoV-2-nuc peptide reactive $\gamma\delta$ sequence repertoires include clonotypes that are highly homologous to TCR δ and γ chain clonotypes of public CD1 reactive $\gamma\delta$ TCRs a) γ CDR3 clonotypes. b) CDR3 of (Y)WG(I)+ V δ 1 clonotypes.

A								
Public CD1 reactive TCRs	V γ CDR3							
	CDR3 region			V γ -segment		J-segment		
DP10.7	CATWD EK	YYKKLF		TRGV4*02		TRGJ1		
AB 18.1	CATWD RNN	KKLF		TRGV4*02		TRGJ2		
C022	CATWD GVGA	YYKKLF		TRGV2*01		TRGJ2		
BC14.1	CATWD VLN	YYKKLF		TRGV4*02		TRGJ2		
C03	CATWD GD	YYKKLF		TRGV4*02		TRGJ2		
V γ clonotypes								
D1	CATWD YL	YYKKLF		TRGV4*02		TRGJ1*02		
	CATWD NPRN	YYKKLF		TRGV8*01		TRGJ1*02		
	CATWD GLT	KKLF		TRGV4*02		TRGJ1*02		
	CATWD GHGC	YYKKLF		TRGV4*02		TRGJ1*02		
	CATWD GPN	YYKKLF		TRGV4*02		TRGJ1*02		
	CATWD THH	YYKKLF		TRGV3*01		TRGJ1*02		
	CATWD REAH	YYKKLF		TRGV3*01		TRGJ1*02		
	CATWD TTRP	YYKKLF		TRGV8*01		TRGJ1*02		
	CATWD SHT	YYKNLF		TRGV8*01		TRGJ1*02		
	CATWD A	YYKKLF		TRGV2*01		TRGJ1*02		
	CATWD RD	YYKKLF		TRGV3*01		TRGJ1*02		
	CATWD GAG	YYKKLF		TRGV2*01		TRGJ1*02		
	CATWD SRGVW	YYKKLF		TRGV5*01		TRGJ1*02		
	CATWD RQRY	YYKKLF		TRGV3*01		TRGJ1*02		
	CATWD RPRI	YYKKLF		TRGV3*01		TRGJ1*02		
	CATWD CG	YYKKLF		TRGV4*02		TRGJ1*02		
D2	CATWD G	YYKKLF		TRGV2*03		TRGJ1*02		
	CATWD GLT	YYKKLF		TRGV4*02		TRGJ1*02		
	CATWD GIG	KKLF		TRGV5*01		TRGJ1*02		
	CATW N	YYKKLF		TRGV8*01		TRGJ1*02		
	CATWE G	YYKKLF		TRGV4*02		TRGJ1*02		
	CATW AM	GYKKLF		TRGV8*01		TRGJ1*02		
	CATWD RQSF	KKLF		TRGV3*01		TRGJ1*02		
B								
Public CD1 reactive TCRs	V δ 1 CDR3							
	V δ 1	...N...	D3	...N...	J1/2	V δ 1-segment	D-segment	J-segment
DP10.7	CALGE	PS	YWG	FPRT	TRVIF	TRDV1*01	TRDD3*01	TRDJ1*01
AB 18.1	CALGD	QIL	YWGL	SH	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
Bai et al.	CALGD	GIPL	YWGIL	TASY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01

(Continued)

TABLE 6 Continued

B								
Public CD1 reactive TCRs	Vδ1 CDR3							
	Vδ1	...N...	D3	...N...	J1/2	Vδ1-segment	D-segment	J-segment
Bai et al.	CALGE	LTV	G	AVH	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
CO22	CALG	PSYM	YWGI	ILD	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
BC14.1	CALGE	RTG	WGF	APLV	TAQLFF	TRDV1*01	TRDD3*01	TRDJ1*01
CO3	CALGE	LR	WP		DKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
(Y)WG(I)+ Vδ1 clonotypes								
D1	CALGE	TGRD	WGY	CD	KLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	QRS	YWG	T	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	LDRLFP	RWGI	I	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	LFL	IWGI	AY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	SSSYP	YWG	TPPLY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	TWG	WGI	RPPY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGD	RNFLPS	YWGI	TY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	QLTFLV	YWGM	GTPY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	LSP	HWGI	LV	TAQLFF	TRDV1*01	TRDD3*01	TRDJ2*01
	CALGE	GVRME	YWGIR	S	WDTRQMF	TRDV1*01	TRDD3*01	TRDJ3*01
D2	CALGE	TSYPRS	YWG	LY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	TSYPRS	YWG	LY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	LVSRRR	WGIR	GGE	LIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALG	IPKALHP	VWGIR	R	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALGE	LAFLYV	YWGIR	PY	TDKLIF	TRDV1*01	TRDD3*01	TRDJ1*01
	CALG	TL	WGIR	FGYRG	QLFF	TRDV1*01	TRDD3*01	TRDJ2*01

CD1-restriction mediating (Y)WG(I) motif in D3 segment are given in bold.

NKRs (93–95). Adaptive Vδ1Cδ-TCRs show true (pauciclonal) expansions in adult and cord blood Vδ1Cδ-TCR-repertoires, are overwhelmingly private, even more so than TCRβ (96), are apparently unrelated both within and between individuals, and their CDR3 lengths are highly variable (96).


Unsurprisingly, Vδ1Cδ-clonotypes in D1 and the non-WGI bearing clonotypes in D2 (3Vδ1Cδ/9) share these characteristics: they are private, inconsistent in CDR3 length due to a high proportion of N or (P) nucleotides (mean 19 and 22 N/P nucleotides; Supplementary Table 2, underlined aa), and lack a conserved motif. The most expanded Vδ1Cδ-clonotypes consistently share strong hydrophobicity in their N-nucleotide-encoded CDR3 though, with ≥50% amino acids being aliphatic combined with (1-3) basic amino acids (R,K,H) in D1 and D2.

Interestingly, motifs YWGI/Y and LGD are both encoded by TRDD3*01 and defined by the reading frame set by TRDV1*01 and D-segment breakpoints and N-nucleotide insertion (97, 98).

Vaccine-reactive Vδ2Cδ clonotypes belong to the adaptive Vδ2-subset

Recent research redefines human Vδ2⁺-T-cell compartment by separating it into an innate (Vγ9⁺) and adaptive (Vγ9^{negative}) subset with distinct functions in (microbial) immune surveillance (99). Vγ9^{negative} Vδ2⁺ cells undergo targeted clonal expansion/differentiation in response to acute viral infection in both peripheral blood and solid tissues, and thus have the ability to mount a pathogen-specific immune response like Vδ1 and αβ-T cells.

The vast majority of Vδ2-clonotypes in this study was private (Supplementary Table 3) with unique V(D)J rearrangements, individual CDR3-length and no relatedness to each other or to clones from the other donor, resembling Vδ1 and adaptive αβ-T cells, which undergo profound and highly focused clonal expansions from an originally diverse and private TCR-repertoire in response to specific immune challenges (84).



Vδ2⁺-clonotypes containing a LGD or GG motif were identified (Figure 6a)

Phosphoantigen (Pag)-reactivity of the Vδ2-clonotypes is unlikely, as corresponding Pag-reactive Vγ9-clonotypes have not been identified. Consistent with an adaptive-like vaccine-reactive Vδ2⁺-phenotype, the γ-repertoires were predominantly Vγ9^{negative} (59/75 in D1; 20/21 in D2). Of the only few Vγ9⁺ (Figure 6b) none was using JP1, the J-segment of Pag-reactive semi-invariant Vγ9JP1Vδ2-TCR, the most abundant γδ-TCR in adult peripheral blood (100, 101)

The few TRGV9⁺-clonotypes (two germline-encoded public sequences (CALWEVQELGKKIKVF TRGV9*01 TRGJP*01) (95, 101) published in context of CMV (102) and Epstein-Barr virus (103) and several private clonotypes (CALWYEELGKKIKVF TRGV9*01/TRGJP*01) contained the JP-segment in D1. D2 had only one single Vγ9⁺-clonotype, which was private (TRGV9*01 TRGJP*01; CALWEAIQELGKKIKVF, Table 7). JP1 however was identified in several Vγ9^{negative} -clonotypes (D1: n=11/D2: n=3) (Figure 6c). In D2, the most expanded clonotype was Vγ2⁺ TRGV2*03-CATWDGYYKKLF, identical to the CD1a-reactive CO3 TCRγ-chain clonotype except for 1 amino acid (88).

Chord diagrams for γ and δ transcripts identify Vδ2⁺-clonotypes as members of the adaptive Vδ2⁺ T-cell subset

Chord diagrams (Figure 6c) do not show the number of clones, but the number of unique sequences with this rearrangement, i.e. how often a clone was represented. For example, in D1 there were

TABLE 7 Underlying sequences of logoplots in Figure 6b.

TRVγ sequences			
Donor	CDR3	V	J
D1	CALWEVLGKLF	TRGV9*01	TRGJ1*02
	CALWEPHGRKKLF	TRGV9*01	TRGJ1*02
	CALWEVQELGKKIKVF	TRGV9*01	TRGJP*01
	CALWYEELGKKIKVF	TRGV9*01	TRGJP*01
	CALWEPQELGKKIKVF	TRGV9*01	TRGJP*01
	CALWEVPELGKKIKVF	TRGV9*01	TRGJP*01
	CALWEVHPSNYYKKLF	TRGV9*01	TRGJ1*02
	CALWEVQELGKKIKVF	TRGV9*01	TRGJP*01
	CALWEVQKELGKKIKVF	TRGV9*01	TRGJP*01
	CALWEVWSELGKKIKVF	TRGV9*01	TRGJP*01
	CALWAPERELGKKIKVF	TRGV9*01	TRGJP*01
	CALWEVLRKLS	TRGV9*01	TRGJ1*02
	CALWEVLGKLF	TRGV9*01	TRGJ1*02
	CALWEVLGKLF	TRGV9*01	TRGJ1*02
	CALWEPHGRKKLF	TRGV9*01	TRGJ1*02
	CALWEATYYKKLF	TRGV9*01	TRGJ1*02
D2	CATWDGYYKKLF	TRGV2*03	TRGJ1*02
	CATWDGATGWFKIF	TRGV2*03	TRGJP1*01
	CATWERVGWFKIF	TRGV2*03	TRGJP1*01

only 16 TRGV9 clones, but they were very common (highly expanded) (Figure 6c). Important to note and as mentioned above: none of these 16 TRGV9 clones used the segment JP1, that segment which is part of the phosphoreactive Vδ2Vγ9 TCRs (Figure 6C). Only one Vγ9 clonotypes was detected in D2.

Taken together, TCR bulk sequencing does not allow for the identification of heterodimers, yet the γ-chain clonotypes detected were mainly Vγ9^{negative} (59/75 and 20/21 γ in D1 and D2 respectively) and almost exclusively private. The few Vγ9⁺ clonotypes did *not* show JP1 prerequisite for Pag-sensing. Therefore, from a purely statistical point of view, this supports the assumption that Vδ2⁺-clonotypes identified in this study belong to the adaptive Vγ9^{negative}Vδ2⁺-T-cell subset (99).

Atypical T-cell clonotypes (γδ, VαCδ, VδCα)

The γδ-T-cell clone HCSHFDPYSALCV and Vδ/Cα clone VLPALLSQTQLGSFPPLRP belong to the overlap repertoire and have atypical CDR3 regions (Tables 4, 8). They lack the conserved Candeias cysteine and the CALGE/CLV motif, but have exceptionally long stretches of N-nucleotides between V and D and D and J segments (D1: 58 and 22, D2: 22 and 8 respectively). Interestingly, the VLPALLSQTQLGSFPPLRP (TRAV23/DV6*01, TRDD2*01, TRDJ4*01, Cα; Tables 4, 8) clonotype is annotated in context of T-cell reconstitution in pediatric patients after HSCT using TCRαβ/CD19-depleted hematopoietic cell grafts, and derived from unproductive TRBV-rearrangements (patient 1: TRBV1*01 TRBD1*01 TRBJ2-3*01 (3 different clone sequences) (Patient 2: TRBV1*01 TRBD2*01 TRBJ2-3*01). HCSHFDPYSALCV (TRAV36/DV7*01, TRDD2*01, TRDJ2*01, Cδ) was not annotated in public databases but was the most frequent γδ-T-cell clone of both donors with 140 and 50 unique sequences in D1 and D2 respectively. Being in the overlapping repertoire makes the clone “public”.

Vα-Cδ TCRs

The two Vα12/Cδ clones, both identified in both donors (Tables 4, 8) resulted from differing underlying rearrangements involving Jα22 or Jα44 fused to TRAV12 respectively. Their CDR3 sequence LPVSF is commonly found in public databases yet annotated for TRAV CDR3 in CD4⁺ T cells αβTCRs (79, 80) and

has been identified in-house in Glioblastoma TIL and γδ cells from healthy donor peripheral blood, albeit each time as VαCδ hybrid clonotypes though (unpublished data).

The Cδ-segment in the Vα-Cδ hybrid clonotype can only pair with a γ-chain to form a γδTCR that recognizes its targets directly or presented by different anchor molecules (81).

Discussion

This study reveals a multi-layered immune response elicited by a single 16-mer aliphatic peptide in two individuals. The small sample size of two individuals are case-level observations and thereby restrict the strength of the conclusions, however this approach reflects the exploratory and descriptive nature of this study while highlighting important clues and patterns worthy of further investigation. A follow-up study will employ more targeted approaches like single-cell TCR sequencing and functional assays of peptide-specific T-cells as well as functional capacity of γδ- and hybrid clonotypes and will be the next important step to build on our molecular findings in this study.

Designed specifically for promiscuous MHC class II binding, LLLDRLNQLESKMS recognizes the important role CD4⁺ T cells play in immune responses to neoantigens (104) and enabled us to study its immunogenicity in the context of allogeneic T cells. We found a similarly robust immune response in both donors following the same principles. The aliphatic nature of the peptide, allowing presentation also via CD1, added a layer of pre-programmed immunity to the adaptive responses. Although using only a small fraction of the cDNA used to sequence adaptive TCRs, we found an abundance of unconventional T cells including (CD1-restricted) Vδ1-, adaptive Vδ2-, and VαCδ clonotypes, complementing the wealth of adaptive T-cell clonotypes.

This finding is significant since γδ-t cells make up the majority of T cells in epithelia where viruses enter the body and are key in the induction and orchestration of the early immune response.

Overlap between the repertoires was small: 15 TRA and 9 TRB clonotypes, one γδ T-cell clone HCSHFDPYSALCV, and in addition two VαCδ (with differing underlying rearrangement) and one VδCα clonotype were found in both donors.

Although representing only a small percentage of the total sequences, the overlap repertoire reveals interesting features: the adaptive clonotypes are not homologous to each, i.e. show neither convergent CDR3 formation nor conserved motifs, and have

TABLE 8 Exotic and hybrid γδTCRs including VδCα, VαCδ, and atypical VδCδ clonotypes.

Exotic rearrangement	CDR3 sequence	Hydrophobic amino acids in CDR3	Public
Hybrid γδTCR (Vδ6/Cα)	VLPALLSQTQLGSFPPLRP	12/19	present in both donors, superpublic
Hybrid γδTCR (Vα12/J44/Cδ)	LPVSF	4/5	present in both donors, superpublic
Hybrid γδTCR (Vα12/J20/Cδ)	LPVSF	4/5	present in both donors, superpublic
γδTCR (Vδ7/Cδ)	HCSHFDPYSALC	8/14	present in both donors, public

Aliphatic amino acids are red, basic amino acids are green.
CDR3 regions are given in bold.

different CDR3 lengths. The $\gamma\delta$ -T-cell clone is atypical, lacking a characteristic 5' CALGE/CACD but showing a large number of N nucleotides, which is more characteristic of conventional adaptive TCR clonotypes. In contrast, clonotypes of adaptive immunity shared between the donors show few or no N nucleotides, identifying them as TdT-independent “neonatal” TCRs.

CDR3-length-fragment analysis with an almost Gaussian profile in the α , β and δ repertoires did not suggest pronounced clonal expansions, nor did clonotype analysis of the most commonly represented CDR3 length fragments. However, the clonotypes examined shared N-nucleotide encoded aliphatic amino acids in their mostly unique CDR3 binding region. Tree plots confirmed the finding of predominantly unique peptide-responsive CDR3 clonotypes in the α and β sequences.

Based on the finding that physicochemical features of the germline-encoded CDR1 and CDR2 regions of the V α and β segments contribute to the specificity of a TCR (62), we identified immunodominant rearrangements in the immune repertoires (Figure 3c). Chord diagrams show the restricted use of a few, i.e. 6 out of a total of 64 TRAV/TRBV-segments used in approximately half of all α and 4, respectively 8/47 functional TRBV-segments in the β -clonotypes in both donors, with several of the segments being identical in both donors. Not surprisingly, the CDR2 regions of the immunodominant segments show an identical germline-encoded motif (SN) (examined for TCR α chains only), their germline-encoded CDR1 regions concordantly harboring up to 5 aliphatic amino acids, strongly suggesting - in analogy to recent work - that these will contact the MHC-presented aliphatic peptide. Finally, the CDR3 regions corresponding to the preferred V-segments consistently show abundant N-nucleotide encoded *aliphatic* amino acids but lack a conserved motif.

These findings are highly consistent with studies by Greenshields-Watson et al, Gao et al, and Wang et al, who concordantly report a TCR-V segment bias in virus-responsive repertoires in infants, adults, and individuals with elite control of HIV, that is based on germline-encoded TCR-MHC contacts with complementary biochemical features of TCR and MHC molecules (62, 105, 106), which is indeed intriguing.

V δ 1C α clonotypes from this study were compared with previously published adaptive immunity clonotypes, and matched exclusively with germline-encoded portions of annotated Covid-19 reactive adaptive T cells, “motifs” that were also shared between our donors.

The reverse approach, i.e. stripping the germline sequences from the V-(D)-J CDR3 regions of the clonotypes, i.e. reducing them to purely N-nucleotide encoded segments, did not lead to the identification of motifs, but highlighted the conservation of their charges for hydrophobicity, both in the α , β and V δ 1C α and even the V δ 1C δ clonotypes.

N-encoded hydrophobic residues as a common feature of all CDR3 binding regions reactive to the vaccine-peptide focus attention on the peptide. Chowell et al. show that hydrophobicity of TCR contact residues is a hallmark of immunogenic epitopes (107). The correlation between hydrophobicity and immunogenicity is so clear that empirical testing is unnecessary

(107). The broad clonotype repertoires induced in both donors by the aliphatic vaccine-peptide strongly support that hydrophobicity is decisive for the immunogenicity of a peptide.

Kanduc et al. indirectly confirm Chowell's statement by showing that hydrophilicity and hydrophobicity characterize the tolerated common peptide sequences and the immunogenic rare peptides, thus forming the physicochemical basis of immunotolerance (108).

Their outstanding findings provide a straightforward rationale for vaccine-peptide development.

Indeed, hydrophobic peptides as a promising approach for vaccine development are already suggested by the fact that the nucleocapsid-derived LLLDRLNQLESKMS is potentially associated with pre-existing T-cell specificities (previous coronavirus responses). The combination of immunogenic hydrophobicity with promiscuous MHC class II-binding is even more promising, as it elicits responses that are noteworthy in several ways: induction of pre-programmed V δ 1 $\gamma\delta$ -clonotypes, V δ 2-clonotypes that can be considered as recruited mainly from the adaptive, V δ 2V γ ^{negative} compartment according to the gamma-repertoire, adaptive V δ 1C α -hybrid-TCRs endowed with immediate, innate properties, and “neonatal”, almost germline-encoded TCRs, which together may constitute a kind of “early sensing” that facilitates adaptive immune responses by preparing the milieu for their initiation and by broadening the scope with adaptive-like responses. At the same time, the α - and β -clonotypes detected in the study - maximally diverse but all reactive to this one peptide - do not correspond to the prototype of an adaptive immune response, at least not the one we know from class I restricted peptides: namely, the induction and strong expansion of several different clones characterized by convergent CDR3 formation and/or motif conservation.

In contrast, the $\alpha\beta$ -T cells in this study tend to exhibit features characteristic of innate T cells: few/no N-nucleotides, preferential V-segment usage with their germline-encoded CDR1 and CDR2 showing preferences for aliphatic/hydrophobic targets - and thus appear to be pre-programmed in their ‘specificity’ - no focus on a few clones, but rather a large collection of unique clonotypes that share one characteristic, their hydrophobic N-nucleotide encoded amino acids in their CDR3 epitope binding region.

Functionality and specificity of V δ C α -hybrid clonotypes was described recently by Pellicci et al. (109) who show that TCRs comprised of a TCR- δ variable gene (V δ 1) fused to joining α and constant α domains, paired with an array of TCR- β chains represent ~50% of all V δ 1⁺ human T cells, which can recognize peptide- and lipid-based Ags presented by human leukocyte antigen (HLA) and CD1d. Thus V δ C α -hybrid clonotypes confer Ag specificity beyond classical understanding of T cell biology and TCR diversity.

Seminal studies by Legut et al. (110) provide molecular and cellular evidence for the productivity of V δ C α -hybrid clonotypes. Both groups demonstrate robust cell surface expression of V δ 1/J α /C α TCRchains. Notably, they found these rearrangements in polyclonal, IL-2-driven human T cell lines and healthy donor repertoires, with broad J α usage—a finding that strongly supports their functional expression.

Also, Volkmar et al. (111) identified human T cell receptors harboring TRDV genes within the TRA chain. This provides additional confirmation of productive rearrangements and surface expression of V δ -J α -C α molecules in human and murine T cell repertoires. These findings corroborate those of Miossec et al. (112), substantiating the reproducibility and biological relevance of these hybrid TCRs across different experimental platforms and donor sources.

That hybrid V δ -J α -C α chains can form functional TCR heterodimers with TCR β chains was evidenced by Volkmar et al. (111) using stainings with the monoclonal antibody BMA031 specifically recognizing a determinant in the constant region of the TCR beta chain. This specificity for the TCR beta constant region underlies its use in discriminating $\alpha\beta$ T cells from $\gamma\delta$ T cells.

Pellici et al. (109), Legut et al. (110), Miossec et al. (112) and Volkmar et al. (111) all propose that V δ C α -hybrid clonotypes may enable unique antigen recognition distinct from typical $\alpha\beta$ or $\gamma\delta$ TCRs, and that these hybrid TCRs remain areas of active investigation.

Critical consideration should be given to the involvement of $\gamma\delta$ -T cells in the immune response. The germline-encoded CDR1 and 2 regions of the V α in V α 12/C δ hybrid-clonotypes suggest MHC class II-restriction/association, and since $\gamma\delta$ -TCRs can also recognize MHC class II directly, even independently of antigen, one can indeed speculate that these TCRs recognize their antigen in an MHC class II-restricted manner.

Also another MHC class II-associated recognition-scenario is conceivable: the MHC-binding groove accommodates peptides based on the formation of conserved hydrogen bonds between the side chains of the MHC molecule and the backbone of the peptide and the occupation of defined pockets by peptide side chains, with anchor residues P1, P4, P6 and P9 in MHC class II (113–116).

While the MHC class I-binding groove is closed, MHC class II is open at both ends, thereby allowing longer peptides or even intact proteins to bind (13–25 peptides, average length is 15 (117)) and to be loaded onto MHC class II (118, 119).

This allows peptide protrusions from the groove at the NH₂ and COOH termini, commonly known as peptide flanking regions (PFRs), which vary in length and composition but have a significant impact on immunodominance/immunogenicity and subsequent T-cell interaction (120–123).

Most interestingly, most immunogenic epitopes generate CD4⁺ T cells that are dependent on these MHC class II-linked peptide flanking residues, and naturally processed HLA class II peptides show highly conserved immunogenic flanking region sequence preferences with a key role for lipophilic residues. In light of this, it seems reasonable to speculate that PFRs may also be targeted by innate immune cells, and recognition of a hydrophobic protruding residue of the vaccine-peptide LLLDRLLNQLESKMS may lie within the multifunctional scope of $\gamma\delta$ -T cells. This would be consistent with the fact that $\gamma\delta$ -TCRs can recognize MHC class II regardless of the peptide presented and regardless of the specificity of the molecule presented (85). And, it would be compatible with the binding properties of V α C δ hybrid-TCRs.

The recognition of hydrophobic residues of peptides by true $\gamma\delta$ -T cells has long been known. Mycobacteria HSP-60-specific $\gamma\delta$ -TCRs structural requirements for stimulation related to the smallest stimulatory mycobacterial HSP-60 peptide FGLQLEL (HSP-60 positions 181–187), are the 5' hydrophobic residues phenylalanine (F) and leucine (L) (positions 181 and 183), in a non-conserved region among HSP-60 molecules of other species, thus $\gamma\delta$ -T cells mediate an epitope and pathogen specific immune response (124).

Remarkably, the unconventional V δ 6C α , the V δ 7/C δ , and the hybrid V α C δ clonotypes of the overlap repertoire (Tables 4, 8), all exhibit significant hydrophobicity with predominantly aliphatic and non-polar aa in their CDR3 regions (Table 8) pointing to a binding preference for hydrophobic moieties.

$\gamma\delta$ -T cells can recognize (peptide-loaded) MHC classes I and II

$\gamma\delta$ -TCR-ligand recognition is a means by which $\gamma\delta$ -T cells discriminate between homeostasis and stress conditions (125).

That this includes MHC class I and II molecules recognition was shown for human HLA-A2 (33), HLA-24 (31), HLA-B27 (32), which can specifically activate/expand human $\gamma\delta$ -T-cell clones from healthy individuals in culture, independent of peptide presentation, thereby $\gamma\delta$ -T-cells recognize conserved parts of the MHC. These findings were expanded by showing that the V γ 5V δ 1⁺TCR – which recognizes HLA-A*24:02 on cancer cells with a key role for CDR1 and CDR2 in MHC binding – is dependent on peptide loading of the HLA complex but *not* the presentation of a *specific* peptide (125). Peptide-presenting MHC-molecules have increased stability on cell surfaces, thus random peptide presentation may confer target stabilization rather than specific antigen presentation.

Finally, direct interaction of expanded V δ 1⁺ TCRs with the MHC-II-complex and massive expansion of individual V δ 1⁺ $\gamma\delta$ -T cell clones during viral infection were described (85).

In this context another report is significant. V δ 1⁺- $\gamma\delta$ -T cells derived *in vitro* from human hematopoietic stem and progenitor cell (HSPC) can react with and expand in response to HLA-A2-presented melanoma antigen MART-1. The binding of the respective $\gamma\delta$ -TCRs to MART-1-pMHC is less peptide-centric as compared to the interaction with a MART-1-specific $\alpha\beta$ -TCR and it is speculated that MART-1 may act as specific stabilizer for the MHC for proper recognition by the respective $\gamma\delta$ -TCRs. Intriguingly, the heteroclite peptide MART-1-(26–35) ELAGIGILTV is highly aliphatic: 8/10 amino acids are hydrophobic.

The potential of induced unconventional T-cell responses

A vaccines potential of inducing unconventional T-cell responses offers substantial immunologic and therapeutic potential by bridging innate and adaptive immunity, particularly at barrier sites where pathogens first contact the host.

Unconventional T cells, such as $\gamma\delta$ T cells, recognize a broad spectrum of antigens, including non-peptide metabolites and lipids presented by non-classical MHC molecules. This enables them to rapidly respond in an innate-like manner, offering early defense that can contain infections before conventional T cells are fully activated (126).

$\gamma\delta$ T cells are preferentially localized at epithelial barrier surfaces—such as the respiratory, gastrointestinal, and urogenital tracts—the main viral entry points. Here, they contribute to barrier immunity by detecting conserved microbial and stress-induced ligands, and as we know according to Davey et al. (95, 98) and the present study: also CD1 or MHC class II presented ligands, promoting local immune responses, maintaining tissue homeostasis, and facilitating repair after injury (96, 99, 127–129). Their capacity for rapid cytokine secretion and cytotoxicity complements physical epithelial defenses and innate immune sensing, enhancing early viral control (130).

Clinically, harnessing unconventional T-cell responses opens new avenues for vaccines and immunotherapies that provide rapid, broad-spectrum protection, especially against pathogens like viruses that exploit barrier tissues. Their relative resistance to exhaustion and pre-expanded tissue presence makes them attractive for therapies targeting infections, but also cancer, and inflammatory diseases (131). Overall, unconventional T cells augment the immune system's plasticity and robustness, particularly at the critical interfaces between host and environment.

In conclusion, the immune response elicited by a single highly aliphatic vaccine peptide, predicted to promiscuously bind to MHC class II and according to its hydrophobic properties is presentable via CD1, seems to suggest two things: First, that the boundaries between adaptive and innate immunity may be more fluid than previously thought, and that $\alpha\beta$ -T cells, which represent the end of an evolutionary process toward specificity, may rely on/cooperate with the intermediate stages of this process – the contribution of innate and hybrid-TCR-bearing T cells – which may contribute non-redundantly but independently to the induction, establishment, and consolidation of specificity, the cornerstone for the formation of long-term memory.

Data availability statement

The subjects' repertoire data are publicly available as part of the AIRR Data Commons on VDJ Server (https://vdjserver.org/community?study_id=PRJNA1232000). The raw fastq sequencing files have been deposited in NCBI's Sequence Read Archive (SRA) and are accessible under the BioProject PRJNA1232000 through the SRA accession numbers SRR32574224 and SRR32574225.

Ethics statement

The studies involving humans were approved by Ethikkommission University Tübingen. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the

publication of any potentially identifiable images or data included in this article.

Author contributions

KS: Formal analysis, Writing – original draft, Conceptualization, Project administration, Supervision, Funding acquisition, Writing – review & editing. NK: Writing – review & editing, Writing – original draft, Investigation, Validation, Formal analysis, Data curation, Software, Methodology, Visualization. H-GR: Writing – review & editing, Conceptualization, Methodology, Resources.

Funding

The author(s) declare financial support was received for the research and/or publication of this article. This study was funded by the Hector Stiftung grant M2111, the Elternförderverein Kinderklinik Tübingen and the Reinhold Beitch Stiftung. NK was supported by the Jürgen Manchot Foundation, Düsseldorf, Germany. The funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.

Acknowledgments

We thank the donors for blood donation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Goldstein JR, Lee RD. Demographic perspectives on the mortality of COVID-19 and other epidemics. *Proc Natl Acad Sci U S A*. (2020) 117:22035–41. doi: 10.1073/pnas.2006392117
- Panagiotou OA, Kosar CM, White EM, Bantis LE, Yang X, Santostefano CM, et al. Risk Factors Associated With All-Cause 30-Day Mortality in Nursing Home Residents With COVID-19. *JAMA Intern Med*. (2021) 181:439–48. doi: 10.1001/jamainternmed.2020.7968
- Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med*. (2020) 383:2451–60. doi: 10.1056/NEJMcP2009575
- Erdal GS, Polat O, Erdem GU, Korkusuz R, Hindilerden F, Yilmaz M, et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. *Int J Clin Oncol*. (2021) 26:826–34. doi: 10.1007/s10147-021-01863-6
- Predecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *Lancet*. (2021) 397:1178–81. doi: 10.1016/S0140-6736(21)00502-X
- Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. *Nat Med*. (2020) 26:1428–34. doi: 10.1038/s41591-020-0995-0
- DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following natural infection and vaccination. *Biochem Biophys Res Commun*. (2021) 538:211–7. doi: 10.1016/j.bbrc.2020.10.060
- Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. *Nat Med*. (2012) 18:274–80. doi: 10.1038/nm.2612
- Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J Virol*. (2010) 84:9318–25. doi: 10.1128/JVI.01049-10
- Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. *Immunol Res*. (2014) 59:118–28. doi: 10.1007/s12026-014-8534-z
- Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. *J Virol*. (2014) 88:11034–44. doi: 10.1128/JVI.01505-14
- Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. *J Virol*. (2010) 84:1289–301. doi: 10.1128/JVI.01281-09
- Güvenel A, Jozwik A, Ascough S, Ung SK, Paterson S, Kalyan M, et al. Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection. *J Clin Invest*. (2020) 130:523–38.
- Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature*. (2020) 584:457–62. doi: 10.1038/s41586-020-2550-z
- Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. *Nat Med*. (2003) 9:1131–7. doi: 10.1038/nm917
- Walton S, Mandaric S, Oxenius A. CD4 T cell responses in latent and chronic viral infections. *Front Immunol*. (2013) 4:105. doi: 10.3389/fimmu.2013.00105
- Malyskhina A, Bruggemann A, Paschen A, Dittmer U. Cytotoxic CD4(+) T cells in chronic viral infections and cancer. *Front Immunol*. (2023) 14:1271236. doi: 10.3389/fimmu.2023.1271236
- Al-Talib M, Dimonte S, Humphreys IR. Mucosal T-cell responses to chronic viral infections: Implications for vaccine design. *Cell Mol Immunol*. (2024) 21:982–98. doi: 10.1038/s41423-024-01140-2
- Rammensee HG, Gouttefangeas C, Heidus S, Klein R, Preuss B, Walz JS, et al. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. *Vaccines (Basel)*. (2021) 9. doi: 10.3390/vaccines9050428
- Ferretti AP, Kula T, Wang Y, Nguyen DMV, Weinheimer A, Dunlap GS, et al. Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. *Immunity*. (2020) 53:1095–107 e3. doi: 10.1016/j.immuni.2020.10.006
- Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, et al. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. *Blood*. (2020) 136:2905–17. doi: 10.1182/blood.202008488
- Amicone M, Borges V, Alves MJ, Isidro J, Ze-Ze L, Duarte S, et al. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. *Evol Med Public Health*. (2022) 10:142–55. doi: 10.1093/emph/eoac010
- Gupta S, Gupta D, Bhatnagar S. Analysis of SARS-CoV-2 genome evolutionary patterns. *Microbiol Spectr*. (2024) 12:e0265423. doi: 10.1128/spectrum.02654-23
- Magazine N, Zhang T, Wu Y, McGee MC, Veggiani G, Huang W. Mutations and Evolution of the SARS-CoV-2 Spike Protein. *Viruses*. (2022) 14. doi: 10.3390/v14030640
- Bessa LM, Guseva S, Camacho-Zarco AR, Salvi N, Maurin D, Perez LM, et al. The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex with its viral partner nsp3a. *Sci Adv*. (2022) 8:eabm4034. doi: 10.1126/sciadv.abm4034
- Chen J, Malone B, Llewellyn E, Grasso M, Shelton PMM, Olinare PDB, et al. Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. *bioRxiv*. (2020). doi: 10.1101/2020.07.08.194084
- McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. *Viruses*. (2014) 6:2991–3018. doi: 10.3390/v6082991
- Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, et al. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. *J Immunother Cancer*. (2019) 7:307. doi: 10.1186/s40425-019-0796-5
- Jung S, Nelde A, Maringer Y, Denk M, Zieschang L, Kammer C, et al. AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients. *Front Oncol*. (2024) 14:1458449. doi: 10.3389/fonc.2024.1458449
- Englisch A, Hayn C, Jung S, Heitmann JS, Hackenbruch C, Maringer Y, et al. iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens. *Front Oncol*. (2024) 14:1441625. doi: 10.3389/fonc.2024.1441625
- Heitmann JS, Tandler C, Marconato M, Nelde A, Habibzadeh T, Rittig SM, et al. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. *Nat Commun*. (2023) 14:5032. doi: 10.1038/s41467-023-40758-0
- Ochoa R, Lunardelli VAS, Rosa DS, Laio A, Cossio P. Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol. *Front Immunol*. (2022) 13:862851. doi: 10.3389/fimmu.2022.862851
- Hu Y, Petroni GR, Olson WC, Czarkowski A, Smolkin ME, Grosh WW, et al. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. *Cancer Immunol Immunother*. (2014) 63:779–86.
- Swartz AM, Congdon KL, Nair SK, Li QJ, Herndon JE 2nd, Suryadevara CM, et al. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. *NPJ Vaccines*. (2021) 6:12. doi: 10.1038/s41541-020-00273-5
- Kovjazin R, Volovitz I, Kundel Y, Rosenbaum E, Medalia G, Horn G, et al. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. *Vaccine*. (2011) 29:4676–86. doi: 10.1016/j.vaccine.2011.04.103
- Hottler A, Marz L, Lubke M, Rammensee HG, Stevanovic S. Broad and Efficient Activation of Memory CD4(+) T Cells by Novel HAdV- and HCMV-Derived Peptide Pools. *Front Immunol*. (2021) 12:700438.
- Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. *Nat Immunol*. (2021) 22:74–85. doi: 10.1038/s41590-020-00808-x
- Jurtz V, Paul S, Andreatta M, Marcantili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. *J Immunol*. (2017) 199:3360–8. doi: 10.4049/jimmunol.1700893
- Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. *Nature*. (2022) 601:617–22. doi: 10.1038/s41586-021-04232-5

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2025.1676455/full#supplementary-material>

40. Castano AR, Tangri S, Miller JE, Holcombe HR, Jackson MR, Huse WD, et al. Peptide binding and presentation by mouse CD1. *Science*. (1995) 269:223–6. doi: 10.1126/science.7542403
41. Tsai B. Penetration of nonenveloped viruses into the cytoplasm. *Annu Rev Cell Dev Biol*. (2007) 23:23–43. doi: 10.1146/annurev.cellbio.23.090506.123454
42. Banerjee M, Johnson JE. Activation, exposure and penetration of virally encoded, membrane-active polypeptides during non-enveloped virus entry. *Curr Protein Pept Sci*. (2008) 9:16–27. doi: 10.2174/138920308783565732
43. Moyer CL, Nemerow GR. Viral weapons of membrane destruction: variable modes of membrane penetration by non-enveloped viruses. *Curr Opin Virol*. (2011) 1:44–9. doi: 10.1016/j.coviro.2011.05.002
44. Ingelmo-Torres M, Gonzalez-Moreno E, Kassan A, Hanzal-Bayer M, Tebar F, Herms A, et al. Hydrophobic and basic domains target proteins to lipid droplets. *Traffic*. (2009) 10:1785–801. doi: 10.1111/j.1600-0854.2009.00994.x
45. Teyton L. Role of lipid transfer proteins in loading CD1 antigen-presenting molecules. *J Lipid Res*. (2018) 59:1367–73. doi: 10.1194/jlr.R083212
46. Gabernet G, Marquez S, Bjornson R, Peltzer A, Meng H, Aron E, et al. nf-core/airflow: An adaptive immune receptor repertoire analysis workflow employing the Immcantation framework. *PLoS Comput Biol*. (2024) 20:e1012265. doi: 10.1371/journal.pcbi.1012265
47. Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. *Nat Biotechnol*. (2017) 35:316–9. doi: 10.1038/nbt.3820
48. Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol*. (2020) 38:276–8. doi: 10.1038/s41587-020-0439-x
49. Vander Heiden JA, Yaari G, Uduman M, Stern JN, O'Connor KC, Hafner DA, et al. pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. *Bioinformatics*. (2014) 30:1930–2. doi: 10.1093/bioinformatics/btu138
50. Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein SH. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. *Bioinformatics*. (2015) 31:3356–8. doi: 10.1093/bioinformatics/btv359
51. Wingett SW, Andrews S. FastQ Screen: A tool for multi-genome mapping and quality control. *F1000Res*. (2018) 7:1338. doi: 10.12688/f1000research
52. Stern JN, Yaari G, Vander Heiden JA, Church G, Donahue WF, Hintzen RQ, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. *Sci Transl Med*. (2014) 6:248ra107. doi: 10.1126/scitranslmed.3008879
53. Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. *Nucleic Acids Res*. (2013) 41:W34–40. doi: 10.1093/nar/gkt382
54. Frith MC, Saunders NF, Kobe B, Bailey TL. Discovering sequence motifs with arbitrary insertions and deletions. *PLoS Comput Biol*. (2008) 4:e1000071. doi: 10.1371/journal.pcbi.1000071
55. R Core Team. R: A language and environment for statistical computing. *Foundation Stat Computing*. (2021). <https://www.r-project.org/>.
56. Wickham H. *ggplot2: elegant graphics for data analysis*. 2nd 2016 ed. Cham: Springer International Publishing (2016).
57. Bedward M, Eppstein D, Menzel P. packcircles: Circle Packing. *R Package version 0.3.5*. (2022). <https://CRAN.R-project.org/package=packcircles>.
58. Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize Implements and enhances circular visualization in R. *Bioinformatics*. (2014) 30:2811–2. doi: 10.1093/bioinformatics/btu393
59. Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. *Nat Biotechnol*. (2020) 38:1194–202. doi: 10.1038/s41587-020-0505-4
60. Corrie BD, Marthandan N, Zimonja B, Jaglale J, Zhou Y, Barr E, et al. iReceptor: A platform for querying and analyzing antibody/B-cell and T-cell receptor repertoire data across federated repositories. *Immunol Rev*. (2018) 284:24–41. doi: 10.1111/imr.2018.284.issue-1
61. Sonntag K, Hashimoto H, Eylich M, Menzel M, Schubach M, Docker D, et al. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipptide vaccines: a case report. *J Transl Med*. (2018) 16:23. doi: 10.1186/s12967-018-1382-1
62. Greenshields-Watson A, Attaf M, MacLachlan BJ, Whalley T, Rius C, Wall A, et al. CD4(+) T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. *Cell Rep*. (2020) 32:107885. doi: 10.1016/j.celrep.2020.107885
63. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, et al. CD1d-lipid antigen recognition by the gammadelta TCR. *Nat Immunol*. (2013) 14:1137–45. doi: 10.1038/ni.2713
64. Trofimov A, Brouillard P, Larouche JD, Seguin J, Laverdure JP, Brasey A, et al. Two types of human TCR differentially regulate reactivity to self and non-self antigens. *iScience*. (2022) 25:104968. doi: 10.1016/j.isci.2022.104968
65. Kockelbergh H, Evans S, Deng T, Clyne E, Kyriakidou A, Economou A, et al. Utility of Bulk T-Cell Receptor Repertoire Sequencing Analysis in Understanding Immune Responses to COVID-19. *Diagnostics (Basel)*. (2022) 12. doi: 10.3390/diagnostics12051222
66. Foers AD, Shoukat MS, Welsh OE, Donovan K, Petry R, Evans SC, et al. Classification of intestinal T-cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status. *J Pathol*. (2021) 253:279–91. doi: 10.1002/path.v253.3
67. Glanville J, Huang H, Nau A, Hattori O, Wagar LE, Rubelt F, et al. Identifying specificity groups in the T cell receptor repertoire. *Nature*. (2017) 547:94–8. doi: 10.1038/nature22976
68. Ritmahan W, Kesmir C, Vroomans RMA. Revealing factors determining immunodominant responses against dominant epitopes. *Immunogenetics* (2020) 72:109–18.
69. Stern MH, Lipkowitz S, Aurias A, Griscelli C, Thomas G, Kirsch IR. Inversion of chromosome 7 in ataxia telangiectasia is generated by a rearrangement between T-cell receptor beta and T-cell receptor gamma genes. *Blood*. (1989) 74:2076–80. doi: 10.1182/blood.V74.6.2076.2076
70. Lipkowitz S, Stern MH, Kirsch IR. Hybrid T cell receptor genes formed by interlocus recombination in normal and ataxia-telangiectasia lymphocytes. *J Exp Med*. (1990) 172:409–18. doi: 10.1084/jem.172.2.409
71. Kobayashi Y, Tycko B, Soreng AL, Sklar J. Transrearrangements between antigen receptor genes in normal human lymphoid tissues and in ataxia telangiectasia. *J Immunol*. (1991) 147:3201–9. doi: 10.4049/jimmunol.147.9.3201
72. Tycko B, Coyle H, Sklar J. Chimeric gamma-delta signal joints. Implications for the mechanism and regulation of T cell receptor gene rearrangement. *J Immunol*. (1991) 147:705–13. doi: 10.4049/jimmunol.147.2.705
73. Tycko B, Palmer JD, Sklar J. T cell receptor gene trans-rearrangements: chimeric gamma-delta genes in normal lymphoid tissues. *Science*. (1989) 245:1242–6. doi: 10.1126/science.2551037
74. Davodeau F, Peyrat MA, Gaschet J, Hallet MM, Triebel F, Vie H, et al. Surface expression of functional T cell receptor chains formed by interlocus recombination on human T lymphocytes. *J Exp Med*. (1994) 180:1685–91. doi: 10.1084/jem.180.5.1685
75. Sottini A, Imberti L, Fiordalisi G, Primi D. Use of variable human V delta genes to create functional T cell receptor alpha chain transcripts. *Eur J Immunol*. (1991) 21:2455–9. doi: 10.1002/eji.1830211023
76. Verschuren MC, Wolvers-Tettero IL, Breit TM, van Dongen JJ. T-cell receptor V delta-J alpha rearrangements in human thymocytes: the role of V delta-J alpha rearrangements in T-cell receptor-delta gene deletion. *Immunology*. (1998) 93:208–12. doi: 10.1046/j.1365-2567.1998.00417.x
77. Giachino C, Rocci MP, Bottaro M, Matullo G, De Libero G, Migone N. T cell receptor V delta 2-C alpha transcripts are present in the thymus but virtually absent in the periphery. *J Immunol*. (1994) 153:1637–44. doi: 10.4049/jimmunol.153.4.1637
78. Minervina AA, Komech EA, Titov A, Bensouda Koraihi M, Rosati E, Mamedov IZ, et al. Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection. *Elife*. (2021) 10. doi: 10.7554/eLife.63502
79. Rowntree LC, Petersen J, Juno JA, Chaurasia P, Wrangé K, Koutsakos M, et al. SARS-CoV-2-specific CD8(+) T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. *Immunol Cell Biol*. (2021) 99:990–1000. doi: 10.1111/imcb.12482
80. Szeto C, Nguyen AT, Lobos CA, Chatzileontiadou DSM, Jayasinghe D, Grant EJ, et al. Molecular Basis of a Dominant SARS-CoV-2 Spike-Derived Epitope Presented by HLA-A*02:01 Recognised by a Public TCR. *Cells*. (2021) 10. doi: 10.3390/cells10102646
81. Born WK, Kemal Aydinoglu M, O'Brien RL. Diversity of gammadelta T-cell antigens. *Cell Mol Immunol*. (2013) 10:13–20. doi: 10.1038/cmi.2012.45
82. Hayday AC. gammadelta T Cell Update: Adaptate Orchestrators of Immune Surveillance. *J Immunol*. (2019) 203:311–20. doi: 10.4049/jimmunol.1800934
83. Benveniste PM, Roy S, Nakatsugawa M, Chen ELY, Nguyen L, Millar DG, et al. Generation and molecular recognition of melanoma-associated antigen-specific human gammadelta T cells. *Sci Immunol*. (2018) 3. doi: 10.1126/sciimmunol.aav4036
84. Benveniste PM, Nakatsugawa M, Nguyen L, Ohashi PS, Hirano N, Zuniga-Pflucker JC. In vitro-generated MART-1-specific CD8 T cells display a broader T-cell receptor repertoire than ex vivo naive and tumor-infiltrating lymphocytes. *Immunol Cell Biol*. (2019) 97:427–34. doi: 10.1111/imcb.2019.97.issue-4
85. Deseke M, Rampoldi F, Sandrock I, Borst E, Boning H, Ssebyatika GL, et al. A CMV-induced adaptive human Vdelta1+ gammadelta T cell clone recognizes HLA-DR. *J Exp Med*. (2022) 219.
86. Van Rhijn J, Le Nours J, CD1 and MR1 recognition by human gammadelta T cells. *Mol Immunol*. (2021) 133:95–100. doi: 10.1016/j.molimm.2020.12.008
87. Luoma AM, Castro CD, Mayassi T, Bembins LA, Bai L, Picard D, et al. Crystal structure of Vdelta1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human gammadelta T cells. *Immunity*. (2013) 39:1032–42. doi: 10.1016/j.immuni.2013.11.001
88. Wegrecki M, Ocampo TA, Gunasinghe SD, von Borstel A, Tin SY, Reijneveld JF, et al. Atypical sideways recognition of CD1a by autoreactive gammadelta T cell receptors. *Nat Commun*. (2022) 13:3872. doi: 10.1038/s41467-022-31443-9

89. Reijneveld JF, Ocampo TA, Shahine A, Gully BS, Vantourout P, Hayday AC, et al. Human gammadelta T cells recognize CD1b by two distinct mechanisms. *Proc Natl Acad Sci U S A*. (2020) 117:22944–52.
90. Zhang XM, Cathala G, Souza Z, Lefranc MP, Huck S. The human T-cell receptor gamma variable pseudogene V10 is a distinctive marker of human speciation. *Immunogenetics*. (1996) 43:196–203. doi: 10.1007/s002510050046
91. Luoma AM, Castro CD, Adams EJ. gammadelta T cell surveillance via CD1 molecules. *Trends Immunol*. (2014) 35:613–21. doi: 10.1016/j.it.2014.09.003
92. Ravens S, Schultze-Florey C, Raha S, Sandrock I, Drenker M, Oberdorfer L, et al. Human gammadelta T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. *Nat Immunol*. (2017) 18:393–401. doi: 10.1038/ni.3686
93. Chien YH, Bonneville M. Gamma delta T cell receptors. *Cell Mol Life Sci*. (2006) 63:2089–94. doi: 10.1007/s00018-006-6020-z
94. Kabelitz D. Human gammadelta T cells: From a neglected lymphocyte population to cellular immunotherapy: A personal reflection of 30 years of gammadelta T cell research. *Clin Immunol*. (2016) 172:90–7. doi: 10.1016/j.clim.2016.07.012
95. Dimova T, Brouwer M, Gosselin F, Tassinon J, Leo O, Donner C, et al. Effector Vgamma9Vdelta2 T cells dominate the human fetal gammadelta T-cell repertoire. *Proc Natl Acad Sci U S A*. (2015) 112:E556–65.
96. Davey MS, Willcox CR, Joyce SP, Ladell K, Kasatskaya SA, McLaren JE, et al. Clonal selection in the human Vdelta1 T cell repertoire indicates gammadelta TCR-dependent adaptive immune surveillance. *Nat Commun*. (2017) 8:14760. doi: 10.1038/ncomms14760
97. Tieppo P, Papadopoulou M, Gatti D, McGovern N, Chan JKY, Gosselin F, et al. The human fetal thymus generates invariant effector gammadelta T cells. *J Exp Med*. (2020) 217.
98. Sanchez Sanchez G, Papadopoulou M, Azouz A, Tafesse Y, Mishra A, Chan JKY, et al. Identification of distinct functional thymic programming of fetal and pediatric human gammadelta thymocytes via single-cell analysis. *Nat Commun*. (2022) 13:5842. doi: 10.1038/s41467-022-33488-2
99. Davey MS, Willcox CR, Hunter S, Kasatskaya SA, Remmerswaal EBM, Salim M, et al. The human Vdelta2(+) T-cell compartment comprises distinct innate-like Vgamma9(+) and adaptive Vgamma9(-) subsets. *Nat Commun*. (2018) 9:1760. doi: 10.1038/s41467-018-04076-0
100. Willcox CR, Davey MS, Willcox BE. Development and Selection of the Human Vgamma9Vdelta2(+) T-Cell Repertoire. *Front Immunol*. (2018) 9:1501. doi: 10.3389/fimmu.2018.01501
101. Delfau MH, Hance AJ, Lecossier D, Vilmer E, Grandchamp B. Restricted diversity of V gamma 9-JP rearrangements in unstimulated human gamma/delta T lymphocytes. *Eur J Immunol*. (1992) 22:2437–43. doi: 10.1002/eji.1830220937
102. Arruda LCM, Gaballa A, Uhlin M. Graft gammadelta TCR Sequencing Identifies Public Clonotypes Associated with Hematopoietic Stem Cell Transplantation Efficacy in Acute Myeloid Leukemia Patients and Unravels Cytomegalovirus Impact on Repertoire Distribution. *J Immunol*. (2019) 202:1859–70. doi: 10.4049/jimmunol.1801448
103. Djaoud Z, Parham P. Dimorphism in the TCRgamma-chain repertoire defines 2 types of human immunity to Epstein-Barr virus. *Blood Adv*. (2020) 4:1198–205. doi: 10.1182/bloodadvances.2019001179
104. Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, et al. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. *Cell*. (2020) 183:818–34 e13. doi: 10.1016/j.cell.2020.09.015
105. Gao K, Chen L, Zhang Y, Zhao Y, Wan Z, Wu J, et al. Germline-Encoded TCR-MHC Contacts Promote TCR V Gene Bias in Umbilical Cord Blood T Cell Repertoire. *Front Immunol*. (2019) 10:2064. doi: 10.3389/fimmu.2019.02064
106. Wang Y, Tsitsiklis A, Devos S, Gao W, Chu HH, Zhang Y, et al. Peptide Centric Vbeta Specific Germline Contacts Shape a Specialist T Cell Response. *Front Immunol*. (2022) 13:847092. doi: 10.3389/fimmu.2022.847092
107. Chowell D, Krishna S, Becker PD, Cocita C, Shu J, Tan X, et al. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. *Proc Natl Acad Sci U S A*. (2015) 112:E1754–62. doi: 10.1073/pnas.1500973112
108. Kanduc D. Hydrophobicity and the Physico-Chemical Basis of Immunotolerance. *Pathobiology*. (2020) 87:268–76. doi: 10.1159/000508903
109. Pellicci DG, Uldrich AP, Le Nours J, Ross F, Chabrol E, Eckle SB, et al. The molecular bases of delta/alphabeta T cell-mediated antigen recognition. *J Exp Med*. (2014) 211:2599–615. doi: 10.1084/jem.20141764
110. Legut M, Cole DK, Sewell AK. The promise of gammadelta T cells and the gammadelta T cell receptor for cancer immunotherapy. *Cell Mol Immunol*. (2015) 12:656–68. doi: 10.1038/cmi.2015.28
111. Volkmar M, Fakhr E, Zens S, Bury A, Offringa R, Gordon J, et al. Identification of TRDV-TRAJ V domains in human and mouse T-cell receptor repertoires. *Front Immunol*. (2023) 14:1286688. doi: 10.3389/fimmu.2023.1286688
112. Miossec C, Faure F, Ferradini L, Roman-Roman S, Jitsukawa S, Ferrini S, et al. Further analysis of the T cell receptor gamma/delta+ peripheral lymphocyte subset. The V delta 1 gene segment is expressed with either C alpha or C delta. *J Exp Med*. (1990) 171:1171–88. doi: 10.1084/jem.171.4.1171
113. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature*. (1991) 351:290–6. doi: 10.1038/351290a0
114. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2. 1 by mass spectrometry. *Sci*. (1992) 255:1261–3. doi: 10.1126/science.1546328
115. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. *Nature*. (1993) 364:33–9. doi: 10.1038/364033a0
116. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. *Nature*. (1994) 368:215–21. doi: 10.1038/368215a0
117. Chiciz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. *Nature*. (1992) 358:764–8. doi: 10.1038/358764a0
118. Kim A, Hartman IZ, Poore B, Boronina T, Cole RN, Song N, et al. Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. *Nat Commun*. (2014) 5:5369. doi: 10.1038/ncomms5369
119. Sette A, Adorini L, Colon SM, Buus S, Grey HM. Capacity of intact proteins to bind to MHC class II molecules. *J Immunol*. (1989) 143:1265–7. doi: 10.4049/jimmunol.143.4.1265
120. Barra C, Alvarez B, Paul S, Sette A, Peters B, Andreatta M, et al. Footprints of antigen processing boost MHC class II natural ligand predictions. *Genome Med*. (2018) 10:84. doi: 10.1186/s13073-018-0594-6
121. Arnold PY, La Gruta NL, Miller T, Vignali KM, Adams PS, Woodland DL, et al. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. *J Immunol*. (2002) 169:739–49. doi: 10.4049/jimmunol.169.2.739
122. Carson RT, Vignali KM, Woodland DL, Vignali DA. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. *Immunity*. (1997) 7:387–99. doi: 10.1016/S1074-7613(00)80360-X
123. Godkin AJ, Smith KJ, Willis A, Tejada-Simon MV, Zhang J, Elliott T, et al. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. *J Immunol*. (2001) 166:6720–7. doi: 10.4049/jimmunol.166.11.6720
124. Fu YX, Vollmer M, Kalataradi H, Heyborne K, Reardon C, Miles C, et al. Structural requirements for peptides that stimulate a subset of gamma delta T cells. *J Immunol*. (1994) 152:1578–88. doi: 10.4049/jimmunol.152.4.1578
125. Deseke M, Prinz I. Ligand recognition by the gammadelta TCR and discrimination between homeostasis and stress conditions. *Cell Mol Immunol*. (2020) 17:914–24. doi: 10.1038/s41423-020-0503-y
126. Lv M, Zhang Z, Cui Y. Unconventional T cells in brain homeostasis, injury and neurodegeneration. *Front Immunol*. (2023) 14:1273459. doi: 10.3389/fimmu.2023.1273459
127. Davey MS, Willcox CR, Baker AT, Hunter S, Willcox BE. Recasting Human Vdelta1 Lymphocytes in an Adaptive Role. *Trends Immunol*. (2018) 39:446–59. doi: 10.1016/j.it.2018.03.003
128. Mayassi T, Barreiro LB, Rossjohn J, Jabri B. A multilayered immune system through the lens of unconventional T cells. *Nature*. (2021) 595:501–10. doi: 10.1038/s41586-021-03578-0
129. Yang J, Yan H. Mucosal epithelial cells: the initial sentinels and responders controlling and regulating immune responses to viral infections. *Cell Mol Immunol*. (2021) 18:1628–30. doi: 10.1038/s41423-021-00650-7
130. Hackstein CP, Klennerman P. MAITs and their mates: "Innate-like" behaviors in conventional and unconventional T cells. *Clin Exp Immunol*. (2023) 213:1–9. doi: 10.1093/cei/uxad058
131. Constantinides MG, Belkaid Y. Early-life imprinting of unconventional T cells and tissue homeostasis. *Science*. (2021) 374:eabf0095. doi: 10.1126/science.abf0095